TREATMENT READING
Late Effects of Treatment for Childhood Cancer (PDQ®)
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
116 sections
- General Information About Late Effects of Treatment for Childhood Cancer
- Prevalence of Late Effects in Childhood Cancer Survivors
- Mortality
- Survivors of adolescent and young adult (AYA) cancers
- Monitoring for Late Effects
- Resources to Support Survivor Care
- Risk-based screening
- Access to risk-based survivor care
- Transition to Survivor Care
- Long-term follow-up programs
- COG long-term follow-up guidelines for childhood and AYA cancer survivors
- Myelodysplastic Syndrome and Acute Myeloid Leukemia Postcytotoxic Therapy (MDS-pCT and AML-pCT)
- Therapy-Related Solid SNs
- Subsequent neoplasms after hematopoietic stem cell transplant (HSCT)
- Breast cancer
- Subsequent versus de novo breast cancer
- Mortality after subsequent breast cancer
- Thyroid cancer
- CNS tumors
- Bone and soft tissue tumors
- Skin cancer
- Skin cancer risk after retinoblastoma
- Lung cancer
- Gastrointestinal (GI) cancer
- Oral cancers
- Urogenital cancers
- Renal carcinoma
- Treatment Risk Factors
- Anthracyclines and related agents
- Anthracycline dose equivalency
- Anthracycline cardioprotection
- Radiation therapy
- Cardiovascular disease
- Cerebrovascular disease
- Venous thromboembolism
- Conventional cardiovascular conditions
- Cognitive outcomes after proton radiation therapy
- ALL and chemotherapy-only CNS therapy
- ALL and steroid therapy
- Radiation therapy
- Chemotherapy
- Radiation therapy
- Chemotherapy
- Posttherapy management
- Treatment-related risk factors for hepatobiliary late effects
- Chemotherapy
- Radiation therapy
- HSCT
- Posttherapy management
- Growth hormone replacement therapy
- Treatment and outcomes associated with central precocious puberty
- Management of TSH deficiency
- Diagnosis and management
- Body composition alterations after treatment for CNS tumors
- Posttherapy management
- Development of thromboembolism during antileukemic therapy
- Chemotherapy affecting testicular function
- Chemotherapy affecting ovarian function
- Respiratory Complications After Radiation Therapy
- Respiratory Complications After Chemotherapy
- Hearing loss and platinum-based therapy
- Hearing loss and cranial radiation therapy
- Treatment-specific effects
- Therapy-Related Factors Affecting the Kidney
- Nephrectomy
- Chemotherapy
- Cisplatin
- Carboplatin
- Ifosfamide
- Methotrexate
- Radiation therapy
- Therapy-Related Bladder Complications
- Chemotherapy
- Radiation therapy
- Surgery
- Late effects are health problems that occur months or years after cancer treatment has ended.
- People who have been treated for cancer need regular screening tests to check for a second cancer.
- The kind of test used to screen for a second cancer depends in part on the kind of cancer treatment the survivors had in the past.
- Heart and blood vessel late effects are more likely to occur after treatment for certain childhood cancers.
- Radiation to the chest and certain types of chemotherapy increase the risk of heart and blood vessel late effects.
- Brain and spinal cord late effects are more likely to occur after treatment of brain tumors and acute lymphoblastic leukemia.
- Problems with the teeth and jaws are more likely to occur after treatment for certain childhood cancers.
- Radiation to the head and neck and certain types of chemotherapy increase the risk of late effects to the teeth and jaws.
- Digestive tract late effects are more likely to occur after treatment for certain childhood cancers.
- Radiation to the bladder, prostate, or testicles and certain types of chemotherapy increase the risk of digestive tract late effects.
- Liver and bile duct late effects are more likely to occur after treatment for certain childhood cancers.
- Certain types of chemotherapy and radiation to the liver or bile ducts increase the risk of late effects.
- Radiation therapy increases the risk of pancreatic late effects.
- Thyroid late effects are more likely to occur after treatment for certain childhood cancers.
- Radiation therapy to the head and neck increases the risk of thyroid late effects.
- Neuroendocrine late effects may be caused after treatment for certain childhood cancers.
- Treatment that affects the hypothalamus or pituitary gland increases the risk of neuroendocrine system late effects.
- Metabolic syndrome is more likely to occur after treatment for certain childhood cancers.
- Radiation therapy increases the risk of metabolic syndrome.
- Weight changes and frailty are late effects that are more likely to occur after treatment for certain childhood cancers.
- Radiation therapy increases the risk of weight changes and frailty.
- Cancer treatments and surgery to remove the spleen increase the risk of immune system late effects.
- Bone and joint late effects are more likely to occur after treatment for certain childhood cancers.
- Radiation therapy, surgery, chemotherapy, and other treatments increase the risk of bone and joint late effects.
- Radiation therapy
- Surgery
- Chemotherapy and other drug therapy
- Stem cell transplant
- Reproductive system late effects are more likely to occur after treatment for certain childhood cancers.
- Surgery, radiation therapy, and certain types of chemotherapy increase the risk of late effects that affect the reproductive system.
- Children of childhood cancer survivors are not affected by the parent's previous treatment for cancer.
- Lung late effects are more likely to occur after treatment for certain childhood cancers.
- Certain types of chemotherapy and radiation to the lungs increase the risk of lung late effects.
- Hearing problems are a late effect that is more likely to occur after treatment for certain childhood cancers.
- Radiation therapy to the brain and certain types of chemotherapy increase the risk of hearing loss.
- Eye and vision problems are a late effect that is more likely to occur after treatment for certain childhood cancers.
- Radiation therapy to the brain or head increases the risk of eye problems or vision loss.
- Kidney problems are a late effect that is more likely to occur after treatment for certain childhood cancers.
- Certain types of chemotherapy increase the risk of kidney late effects.
- Bladder problems are a late effect that is more likely to occur after treatment for certain childhood cancers.
- Surgery to the pelvic area and certain types of chemotherapy increase the risk of bladder late effects.
General Information About Late Effects of Treatment for Childhood Cancer
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
During the past five decades, dramatic progress has been made in the development of curative therapies for pediatric malignancies. More than 80% of children with cancer who have access to contemporary therapies are expected to survive into adulthood.[1] The therapies responsible for this survival can also produce adverse, long-term, health-related outcomes, referred to as late effects, which appear months to years after completion of cancer treatment.
Sources: 1
Many approaches have been used to study the very long-term morbidity associated with childhood cancer and its contribution to early mortality. These initiatives have used a spectrum of resources, including data from the following:
High-quality data is needed to establish the occurrence of and risk profiles for late cancer treatment–related toxicity. The highest quality data typically comes from studies that report outcomes in survivors who have undergone medical assessments that provide well-characterized clinical statuses, treatment exposures, and specific late effects. Regardless of study methodology, it is important to consider selection and participation bias of the cohort studies in the context of the findings.
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Prevalence of Late Effects in Childhood Cancer Survivors
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Late effects are common in adults who have survived childhood cancer. Their prevalence increases as time from cancer diagnosis elapses. Multi-institutional and population-based studies have shown excess risk of hospital-related morbidity among childhood and young adult cancer survivors compared with age- and sex-matched controls, with some evidence that this risk is disproportionately high among survivors of racial and ethnic minority populations.[3,9-13]
Among adults who were treated for cancer during childhood, late effects contribute to a high burden of morbidity. Research has shown the following:[4,7,14-18]
60% to more than 90% of survivors develop one or more chronic health conditions.
20% to 80% of survivors experience severe or life-threatening complications during adulthood.
Morbidity accumulation is accelerated in young adult survivors of childhood cancer, compared with that of siblings and the general population. Accumulation of chronic diseases predicts risk of early mortality.[19]
Sources: 19
The St. Jude Life (SJLIFE) cohort study aimed to describe the cumulative burden of cancer therapy using the cumulative burden metric, which incorporates multiple health conditions and recurrent events into a single metric that takes into account competing risks. By age 50 years, survivors in this cohort experienced an average of 17.1 chronic health conditions, 4.7 of which were severe/disabling, life threatening, or fatal.[16] This finding contrasts with the cumulative burden in matched community controls, who experienced 9.2 chronic health conditions, 2.3 of which were severe/disabling, life threatening, or fatal (see Figure 1).[16]
SJLIFE cohort study investigators compared the cumulative burden of chronic health conditions among 4,612 adolescent and young adult survivors at the ages of 18 years (the time of transition from pediatric to adult health care systems) and 26 years (the time of transition from family to individual health insurance plans) with that of 625 controls.[20]
Sources: 20
Survivors at the age of 18 years experienced an average of 22.3 disabling conditions per 100 individuals versus 3.5 in controls, and 128.7 lower-severity conditions (at risk of progressing to higher-grade disabling conditions) versus 12.4 in controls.
Survivors at the age of 26 years experienced an average of 40.3 disabling conditions per 100 individuals versus 5.7 in controls, and 240.5 lower-severity conditions versus 51.3 in controls.
The cumulative burden of disabling, disease-specific conditions at the ages of 18 and 26 years was most notable for survivors of bone tumors (musculoskeletal: 99.9 and 121.70, respectively), soft tissue sarcomas (musculoskeletal: 49.5 and 54.1, respectively), and central nervous system (CNS) tumors (neurological: 24.7 and 36.8, respectively).
The cumulative burden of lower-severity conditions (potentially amenable to intervention) at the ages of 18 and 26 years was most notable for neurological conditions across most cancer subgroups, with the highest cumulative burden in CNS tumor survivors (95.2 and 162.3, respectively).
These findings highlight the importance of optimizing access to health care and health insurance as survivors age and can no longer participate in pediatric health care systems.
The variability in prevalence is related to differences in the following:
Age and follow-up time of the cohorts studied.
Methods and consistency of assessment (e.g., self-reported vs. risk-based medical evaluations).
Treatment intensity and treatment era.
Childhood Cancer Survivor Study (CCSS) investigators demonstrated that the elevated risk of morbidity and mortality among aging survivors in the cohort increases beyond the fourth decade of life. By age 50 years, the cumulative incidence of a self-reported severe, disabling, life-threatening, or fatal health condition was 53.6% among survivors, compared with 19.8% among a sibling control group. Among survivors who reached age 35 years without a previous severe, disabling, life-threatening, or fatal health condition, 25.9% experienced a new grade 3 to grade 5 health condition within 10 years, compared with 6.0% of healthy siblings.[4]
Sources: Childhood Cancer Survivor Study · 4
The presence of serious, disabling, and life-threatening chronic health conditions adversely affects the health status of aging survivors. The greatest impact is on functional impairment and activity limitations. Predictably, chronic health conditions have been reported to contribute to a higher prevalence of emotional distress symptoms in adult survivors than in population controls.[21] Female survivors demonstrate a steeper trajectory of age-dependent decline in health status than do male survivors.[22] The even-higher prevalence of late effects among cohorts evaluated by clinical assessments is related to the subclinical and undiagnosed conditions detected by screening and surveillance measures.[7]
CCSS investigators also evaluated the impact of race and ethnicity on late outcomes. The study compared late mortality, subsequent neoplasms, and chronic health conditions in Hispanic (n = 750) and non-Hispanic Black (n = 694) participants with those in non-Hispanic White participants (n = 12,397).[23] The following results were observed:
Sources: 23
Cancer treatment did not account for disparities in mortality, chronic health conditions, or subsequent neoplasms observed among the groups.
Differences in socioeconomic status and cardiovascular risk factors affected risk. All-cause mortality was higher among non-Hispanic Black participants than among other groups, but this difference disappeared after adjustment for socioeconomic status.
Risk of developing diabetes was elevated among racial and ethnic minority groups even after adjustment for socioeconomic and obesity status.
Non-Hispanic Black patients had a higher likelihood of reporting cardiac conditions, but this risk diminished after adjusting for cardiovascular risk factors.
Nonmelanoma skin cancer was not reported by non-Hispanic Black participants, a finding that has been replicated by other studies.[24] Hispanic participants had a lower risk of nonmelanoma skin cancer than non-Hispanic White participants.
Sources: 24
Recognition of late effects, concurrent with advances in cancer biology, radiological sciences, and supportive care, has resulted in a change in the prevalence and spectrum of treatment effects. In an effort to reduce and prevent late effects, contemporary therapy for most pediatric malignancies has evolved to a risk-adapted approach that is assigned on the basis of a variety of clinical, biological, and sometimes genetic factors.
The CCSS reported that with decreased cumulative dose and frequency of therapeutic radiation from 1970 to 1999, survivors have experienced a significant decrease in risk of subsequent neoplasms.[25]
Sources: 25
With the exception of survivors requiring intensive multimodality therapy for refractory/relapsed malignancies, life-threatening treatment effects are relatively uncommon after contemporary therapy in early follow-up (up to 10 years after diagnosis).
However, survivors still frequently experience life-altering morbidity related to effects of cancer treatment on endocrine, reproductive, musculoskeletal, and neurological function.
A CCSS investigation examined temporal patterns in the cumulative incidence of severe to fatal chronic health conditions among survivors treated from 1970 to 1999.[26]
Sources: 26
The 20-year cumulative incidence of at least one grade 3 to 5 chronic condition decreased significantly, from 33.2% for survivors diagnosed between 1970 and 1979, to 29.3% for those diagnosed between 1980 and 1989, to 27.5% for those diagnosed between 1990 and 1999, compared with a 4.6% incidence in a sibling cohort.
The overall decrease in incidence of chronic conditions across the three treatment decades was, in part, because of a substantial reduction of endocrinopathies, subsequent malignant neoplasms (SMNs), musculoskeletal conditions, and gastrointestinal conditions, whereas the cumulative incidence of hearing loss increased during this time.
Declines in morbidity were not uniform across the diagnosis groups or condition types because of differences in treatment and survival patterns over time. For more information, see Figure 2.
Sources: Figure 2
Despite declines in chronic health conditions over time, self-reported health status has not improved in more recent treatment eras. This finding may be because of the survival of children with higher-risk disease who would have previously died of cancer, or an enhanced awareness of and surveillance for late effects among more recently treated survivors.[27]
Sources: 27
Mortality
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Late effects also contribute to an excess risk of premature death among long-term survivors of childhood cancer, as observed in the following studies:
Several studies of large cohorts of survivors have reported early mortality among individuals treated for childhood cancer, compared with age- and sex-matched general population controls. Relapsed/refractory primary cancer remains the most frequent cause of death, followed by excess cause-specific mortality from subsequent primary cancers, and cardiac and pulmonary toxicity.[28-33]
A CCSS study evaluated specific health-related causes of late mortality and excess deaths, compared with the general U.S. population to identify targets to reduce future risk.[33]
Sources: 33
A CCSS study evaluated specific health-related causes of late mortality and excess deaths, compared with the general U.S. population to identify targets to reduce future risk.[33]
At a median follow-up of 29 years from diagnosis, the 40-year cumulative all-cause mortality rate was 23.3%, with 51.2% of deaths attributed to health-related causes.
Survivors who were 40 or more years from diagnosis experienced 131 excess health-related deaths per 10,000 person-years (95% confidence interval [CI], 111–163). Excess deaths were most commonly related to cancer (absolute excess risk per 10,000 person-years, 54; 95% CI, 41–68), heart disease (27; 18–38), and cerebrovascular disease (10; 5–17).
Healthy lifestyle (assessed by smoking status, alcohol consumption, physical activity, body mass index, and absence of hypertension and diabetes) were each associated with a 20% to 30% reduction in health-related mortality, independent of other factors.
An analysis of the CCSS and Surveillance, Epidemiology, and End Results (SEER) Program data evaluated conditional survival. The study demonstrated a subsequent 5-year survival rate of 92% or higher among most diagnoses at 5 years, 10 years, 15 years, and 20 years. Among those who had survived at least 5 years from diagnosis, the probability of all-cause mortality in the next 10 years was 8.8% in the CCSS and 10.6% in the SEER study, with neoplasms accounting for cause of death in approximately 75% of survivors.[34]
Sources: 34
Despite high premature morbidity rates, overall mortality has decreased over time.[28,30,31,35,36]
CCSS investigators evaluated all-cause and health-related late mortality (including late effects of cancer therapy), SMNs, chronic health conditions, and neurocognitive outcomes among 6,148 survivors of childhood acute lymphoblastic leukemia (median age, 27.9 years; range, 5.9–61.9 years) diagnosed between 1970 and 1999.[37]
Sources: 37
Overall, the 20-year all-cause late mortality rate was 6.6%.
Compared with participants who were treated in the 1970s, patients who were treated with risk-stratified regimens in the 1990s experienced lower health-related late mortality (rate ratio: 1990s standard risk, 0.2; 1990s high risk, 0.3), which was comparable to the U.S. population (standardized mortality ratio [SMR]: 1990s standard risk, 1.3; 1990s high risk, 1.7).
The risk of late mortality and serious chronic health conditions have decreased over time among survivors of acute myeloid leukemia (AML). CCSS investigators evaluated the long-term morbidity, mortality, and health status of more than 800 5-year survivors of childhood AML based on treatment and treatment era. Survivors were compared by treatment group (hematopoietic stem cell transplant [HSCT]); chemotherapy with cranial radiation [CRT]; chemotherapy only) and decade of diagnosis.[38]
Sources: 38
Among 856 survivors, the 20-year late mortality cumulative incidence was highest after HSCT (13.9%; chemotherapy with CRT, 7.6%; chemotherapy only, 5.1%).
Mortality cumulative incidence decreased for survivors of HSCT diagnosed in the 1990s (8.5%) compared with the 1970s (38.9%), as did standardized mortality rates.
Self-reported health status was good to excellent for 88.2% of childhood AML survivors, regardless of treatment.
Most survivors did not experience any grade 3 to 5 chronic health conditions after 20 years (HSCT, 45.8%; chemotherapy with CRT, 23.7%; chemotherapy only, 27.0%).
A temporal reduction in chronic health conditions cumulative incidence was seen after HSCT (1970s, 76.1%; 1990s, 38.3%; P = .02), mirroring a reduction in total-body irradiation use.
Population-based data from a state cancer registry was used to evaluate differences in survival and long-term outcomes by race and ethnicity among 4,222 children diagnosed with cancer between 1987 and 2012.[12]
Sources: 12
Compared with non-Hispanic White children, hospitalization was 70% (hazard ratio [HR], 1.7) more common 5 or more years after diagnosis for American Indian and Alaskan Native children and 50% (HR, 1.5) more common for Black children.
Among survivors at 5 or more years from diagnosis, 2.3-fold to 3.6-fold statistically significant relative increases were observed for hospitalizations for specific conditions for American Indian and Alaskan Native children (HR, 2.3 for infection-related conditions; HR, 3.0 for hematologic-related conditions; HR, 2.6 for digestive-related conditions). The greatest increases were noted for mental health–related conditions (HR, 3.6), a pattern also noted for Black children (HR, 2.5).
An SJLIFE cohort study explored associations between modifiable chronic health conditions and late mortality within the context of social determinants of health.[39]
Sources: 39
Among 9,440 5-year childhood cancer survivors included in the analysis (median age at last follow-up, 27.5 years; median follow-up, 18.8 years), all-cause mortality (SMR, 7.6; 95% CI, 7.2–8.1) and health-related late mortality (SMR, 7.6; 95% CI, 7.0–8.2) was significantly higher than expected for U.S. mortality rates.
Among 3,407 adult participants who completed an on-campus assessment (median age at assessment, 35.4 years; median follow-up, 27.3 years), significant increases in late all-cause and health-related deaths were associated with the number of modifiable chronic health conditions, living in a U.S. census block associated with a high area deprivation index, and frailty.
Specific associations for excess health-related mortality included: one grade 2 modifiable chronic health condition (rate ratio [RR], 2.2; 95% CI, 1.1–4.4), two grade 2 modifiable chronic health conditions (RR, 2.5; 95% CI, 1.2–5.2), three grade 2 modifiable chronic health conditions (RR, 4.0; 95% CI, 1.9–8.4), area deprivation index in 51st to 80th percentile (RR, 9.2; 95% CI, 1.2–69.7), area deprivation index in 81st to 100th percentile (RR, 16.2; 95% CI, 2.1–123.7), and frailty (RR, 2.3; 95% CI, 1.2–4.1).
The CCSS and an SJLIFE cohort study investigated the contribution of cancer-predisposing variants to the risk of SMN-related late mortality (5 years or more after diagnosis).[40]
Sources: 40
Among 12,469 participants (6,172 male and 6,297 female), including 4,402 from the SJLIFE cohort (median follow-up time since collection of first biospecimen, 7.4 years) and 8,067 from the CCSS cohort (median follow-up time since collection of the first biospecimen, 12.6 years), 641 (5.1%) carried cancer-predisposing variants.
Cancer-predisposing variants were significantly associated with an increased severity of SMNs (common terminology criteria for adverse events grade ≥4 vs. grade <4: odds ratio [OR], 2.15; 95% CI, 1.18–4.19).
SMN-related deaths occurred in 263 participants (2.1%), and other-cause deaths occurred in 426 survivors (3.4%).
At 10 years after the first biospecimen collection, the cumulative SMN-related mortality rate in carriers of cancer-predisposing variants was 3.7% (95% CI, 1.2%–8.5%) in SJLIFE and 6.9% (4.1%–10.7%) in CCSS. In comparison, the cumulative SMN-related mortality rate in noncarriers was 1.5% (1.0%–2.1%) in SJLIFE and 2.1% (1.7%–2.5%) in CCSS.
Carrying a cancer-predisposing variant was associated with an increased risk of SMN-related mortality (SJLIFE: HR, 3.40; 95% CI, 1.37–8.43; CCSS: HR, 3.58; 95% CI, 2.27–5.63).
Survivors of adolescent and young adult (AYA) cancers
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Little information is available on late mortality among survivors of AYA cancer.[41-44]
Using SEER data, conditional relative survival up to 25 years after diagnosis was studied in a cohort of AYA patients (N = 205,954) diagnosed with a first malignant cancer (thyroid, melanoma, testicular, breast, lymphoma, leukemia, and CNS tumors).[41]
Sources: 41
Using SEER data, conditional relative survival up to 25 years after diagnosis was studied in a cohort of AYA patients (N = 205,954) diagnosed with a first malignant cancer (thyroid, melanoma, testicular, breast, lymphoma, leukemia, and CNS tumors).[41]
For all cancer types combined, among individuals who survived up to 5 years, the subsequent 5-year relative survival rate exceeded 95% by 7 years after diagnosis.
Most AYA cancer patients who survived at least 7 years after diagnosis experienced little difference in survival compared with the general population.
For specific cancer types, including CNS tumors, female breast cancer, Hodgkin lymphoma, and leukemia, evidence of excess mortality risk persisted, or re-emerged, more than 10 years after a cancer diagnosis.
Conditional relative survival was lowest for AYA patients with CNS tumors, although patients aged 15 to 29 years demonstrated a higher survival rate than did patients aged 30 to 39 years at the time of diagnosis of their CNS tumors.
A separate analysis of 5-year survivors of AYA cancer (aged 15–39 years at diagnosis), also using SEER data (N = 282,969), demonstrated the following:[42]
Sources: 42
A separate analysis of 5-year survivors of AYA cancer (aged 15–39 years at diagnosis), also using SEER data (N = 282,969), demonstrated the following:[42]
The 10-year all-cause mortality rate decreased from 8.3% for those diagnosed between 1975 and 1984 to 5.4% for those diagnosed between 2005 and 2011.
The decrease in mortality primarily resulted from fewer deaths from the initial cancer.
CCSS investigators compared chronic health conditions and all-cause and cause-specific mortality among 5,804 survivors of early-AYA cancer survivors (cancer diagnosis, age 15–20 years; median age, 42 years) and 5,804 childhood cancer survivors (cancer diagnosis, age <15 years; median age, 34 years) matched on primary cancer diagnosis.[43]
Sources: 43
CCSS investigators compared chronic health conditions and all-cause and cause-specific mortality among 5,804 survivors of early-AYA cancer survivors (cancer diagnosis, age 15–20 years; median age, 42 years) and 5,804 childhood cancer survivors (cancer diagnosis, age <15 years; median age, 34 years) matched on primary cancer diagnosis.[43]
The SMR was 5.9 (95% CI, 5.5–6.2) for early-AYA survivors and 6.2 (95% CI, 5.8–6.6) for younger childhood cancer survivors, compared with the general population.
Early-AYA survivors had lower SMRs for death from health-related causes than did childhood cancer survivors (SMR, 4.8 [95% CI, 4.4–5.1] vs. 6.8 [95% CI, 6.2–7.4]), which was primarily evident more than 20 years after cancer diagnosis.
Early-AYA and childhood cancer survivors were at greater risk of developing severe and disabling, life-threatening, or fatal (grades 3–5) health conditions than were siblings of the same age (HR, 4.2 [95% CI, 3.7–4.8] for early-AYA and 5.6 [95% CI, 4.9–6.3] for childhood cancer survivors), although the risk was lower for early-AYA survivors than for childhood cancer survivors.
In a retrospective, population-based cohort study from Kaiser Permanente, cause-specific mortality in 2-year survivors (N = 10,574) of AYA cancers (patients aged 13–39 years who were diagnosed between 1990 and 2012) was examined and compared with individuals without cancer.[45]
Sources: 45
In a retrospective, population-based cohort study from Kaiser Permanente, cause-specific mortality in 2-year survivors (N = 10,574) of AYA cancers (patients aged 13–39 years who were diagnosed between 1990 and 2012) was examined and compared with individuals without cancer.[45]
AYA cancer survivors were at a 10.4-fold increased risk of death compared with the matched noncancer cohort, and this risk remained elevated at more than 20 years after diagnosis (incidence rate ratio [IRR], 2.9).
Beginning at 15 years after diagnosis, the incidence of second cancer–related mortality exceeded the rate of recurrence-related mortality.
Mortality risk of suicide was doubled in AYA cancer survivors compared with the noncancer cohort.
Chronic comorbidities were investigated in a retrospective, population-based cohort study of 6,778 2-year AYA cancer survivors diagnosed and monitored at Kaiser Permanente.[46]
Sources: 46
Chronic comorbidities were investigated in a retrospective, population-based cohort study of 6,778 2-year AYA cancer survivors diagnosed and monitored at Kaiser Permanente.[46]
Approximately 17% of the survivors developed more than one comorbidity. The most common comorbidities were dyslipidemia (22 per 1,000 person-years), hypertension (16 per 1,000 person-years), diabetes (10 per 1,000 person-years), thyroid disorders (9 per 1,000 person-years), and severe depression or anxiety (8 per 1,000 person-years).
IRRs were higher in survivors than in controls without a history of cancer for avascular necrosis (IRR, 8.25), followed by osteoporosis (IRR, 5.75), joint replacement (IRR, 3.89), stroke (IRR, 3.19), premature ovarian failure (IRR, 2.87), and cardiomyopathy or heart failure (IRR, 2.64).
For survivors of AYA cancer, the prevalence of multiple comorbidities approached 40% at 10 years after index date (a 2-year time point from diagnosis), compared with 20% for those without cancer (P < .001).
Monitoring for Late Effects
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Recognition of both acute and late modality–specific toxicity has motivated investigations evaluating the pathophysiology and prognostic factors for cancer treatment–related effects. Consequently, the results of late effects research have played an important role in the following areas:
Changing pediatric cancer therapeutic approaches to reduce treatment-related mortality among survivors treated in more recent eras.[47]
Sources: 47
The development of risk counseling and health screening recommendations for long-term survivors by identifying the clinical and treatment characteristics of those at highest risk of therapy-related complications.[48]
Sources: 48
The common late effects of pediatric cancer encompass several broad domains, including the following:
Growth and development.
Organ function.
Reproductive capacity and health of offspring.
Secondary carcinogenesis.
Psychosocial sequelae related to the primary cancer, its treatment, or maladjustment associated with the cancer experience.
Late sequelae of therapy for childhood cancer can be anticipated based on therapeutic exposures, but the magnitude of risk and the manifestations in an individual patient are influenced by numerous factors. Multiple factors should be considered in the risk assessment for a given late effect (see Figure 3).[49]
Cancer-related factors:
Organs or tissues affected by the cancer.
Direct tissue effects.
Cancer-induced organ dysfunction or other tissue effects.
Treatment-related factors:
Radiation therapy: Total dose, fraction size, organ or tissue volume exposed.
Chemotherapy: Agent type, dose-intensity, cumulative dose, schedule.
Surgery: Technique, site, consequential organ dysfunction.
HSCT.
Combined-modality effects (therapeutic interactions).
Blood product transfusion.
Chronic graft-versus-host disease.
Host-related factors:
Sex.
Genetic predisposition.
Premorbid, comorbid, posttreatment health states and exposures.
Developmental status (age).
Time from diagnosis/therapy.
Inherent tissue sensitivities and capacity for normal tissue repair.
Hormonal milieu.
Socioeconomic status.
Health habits.
Resources to Support Survivor Care
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Risk-based screening
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
The need for long-term follow-up of childhood cancer survivors is supported by the American Society of Pediatric Hematology/Oncology, the International Society of Pediatric Oncology, the American Academy of Pediatrics, the Children’s Oncology Group (COG), and the Institute of Medicine. A risk-based medical follow-up is recommended, which includes a systematic plan for lifelong screening, surveillance, and prevention that incorporates risk estimates based on the following:[49]
Sources: 49
Previous cancer.
Cancer therapy.
Genetic predisposition.
Lifestyle behaviors.
Comorbid conditions.
Sex.
Part of long-term follow-up also focuses on appropriate screening of educational and vocational progress. Specific treatments for childhood cancer, especially those that directly impact nervous system structures, may result in sensory, motor, and neurocognitive deficits that may have adverse effects on functional status, educational attainment, and future vocational opportunities. In support of this, a CCSS investigation observed the following:[50]
Sources: 50
Treatment with cranial radiation doses of 25 Gy or higher was associated with higher odds of unemployment (health related: OR, 3.47; 95% CI, 2.54–4.74; seeking work: OR, 1.77; 95% CI, 1.15–2.71).
Unemployed survivors reported higher levels of poor physical functioning than employed survivors, had lower education and income, and were more likely to be publicly insured than unemployed siblings.
These data emphasize the importance of facilitating survivor access to individualized education services, which has been demonstrated to have a positive impact on education achievement.[51] These services may in turn enhance vocational opportunities.
Sources: 51
In addition to risk-based screening for medical late effects, the impact of health behaviors on cancer-related health risks is also emphasized. Health-promoting behaviors are stressed for survivors of childhood cancer. Educational efforts focused on healthy lifestyle behaviors include the following:
Abstinence from smoking, excess alcohol use, and illicit drug use to reduce the risk of organ toxicity and, potentially, subsequent neoplasms.
Healthy dietary practices (e.g., a diet rich in plant foods and moderate in animal foods) [52] and active lifestyle to reduce treatment-related metabolic and cardiovascular complications.
Sources: 52
Regular physical activity to reduce neurocognitive problems and enhance psychological outcomes.[53,54]
Regular physical activity to reduce neurocognitive problems and enhance psychological outcomes.[53,54]
Survivors who engaged in consistent physical activity over time had fewer neurocognitive problems, including difficulties with task efficiency, emotional regulation, organization, and memory. They also experienced larger neurocognitive improvements, compared with those who had inconsistent activity levels.[53]
Sources: 53
Vigorous exercise in survivors has been associated with a lower prevalence of depression and somatization, as well as less impairment in physical functioning, general health and vitality, emotional role limitations, and mental health quality-of-life domains.[54]
Sources: 54
Access to risk-based survivor care
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Most childhood cancer survivors do not receive recommended risk-based care. The CCSS observed the following:
92.8% of survivors reported receiving some form of medical care in the previous year.[58]
Sources: 58
Nearly 40% reported receiving care that focused on their previous cancer (survivor-focused care).[58]
Sources: 58
Surveillance for new cases of cancer was very low in survivors at the highest risk of colon, breast, or skin cancer, suggesting that survivors and their physicians need education about the risk of subsequent neoplasms and recommended surveillance.[59]
Sources: 59
Sociodemographic factors have been linked to declining rates of follow-up care over time from diagnosis. CCSS participants who were male, had a household income of less than $20,000 per year, and had lower educational attainment (high school education or less) were more likely to report no care at their most recent follow-up survey. This trend is concerning because the prevalence of chronic health conditions increases with longer elapsed time from cancer diagnosis in adults treated for cancer during childhood.[60]
Sources: 60
A study that included 975 adult survivors of childhood cancer identified factors associated with attending the recommended risk-based, cancer-related medical visits. The relative risk of having a cancer-related visit was higher among survivors who:[61]
Sources: 61
A study that included 975 adult survivors of childhood cancer identified factors associated with attending the recommended risk-based, cancer-related medical visits. The relative risk of having a cancer-related visit was higher among survivors who:[61]
Assigned a greater importance to these visits.
Perceived a greater susceptibility to health problems.
Had experienced a cancer-related chronic health problem that was moderate to life-threatening.
Were seeing a primary care provider for a cancer-related problem.
Had received a cancer treatment care plan.
Expressed greater confidence in physicians’ abilities to address questions and concerns.
Access to health insurance appears to play an important role in risk-based survivor care.[62,63] Lack of access to health insurance affects the following:
Cancer-related visits. In the CCSS, uninsured survivors were less likely than those privately insured to report a cancer-related visit (adjusted relative risk, 0.83; 95% CI, 0.75–0.91) or a cancer center visit (adjusted relative risk, 0.83; 95% CI, 0.71–0.98). Uninsured survivors had lower levels of utilization in all measures of care than privately insured survivors. In contrast, publicly insured survivors were more likely to report a cancer-related visit (adjusted relative risk, 1.22; 95% CI, 1.11–1.35) or a cancer center visit (adjusted relative risk, 1.41; 95% CI, 1.18–1.70) than were privately insured survivors.[62]
Sources: 62
Health care outcomes. In a study comparing health care outcomes for long-term AYA cancer survivors with young adults who have no cancer history, the proportion of uninsured survivors did not differ between the two groups.[64]
Sources: 64
Financial burden. Subgroups of adult survivors of childhood cancer may be at additional risk of health care barriers due to financial hardship. Younger survivors (aged 20–29 years), females, non-White survivors, and survivors reporting poorer health faced more cost barriers, which may inhibit the early detection of late effects.[64] Survivors are more likely than their siblings to forego needed medical care related to financial challenges.[65]
Overall, lack of health insurance—related to health issues, unemployment, and other societal factors—remains a significant concern for survivors of childhood cancer.[66,67] Legislation, including the Health Insurance Portability and Accountability Act (HIPAA),[68,69] has improved access and retention of health insurance among survivors, although the quality and limitations associated with these policies have not been well studied.
Transition to Survivor Care
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Long-term follow-up programs
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Transition of care from the pediatric to adult health care setting is necessary for most childhood cancer survivors in the United States.
When available, multidisciplinary long-term follow-up programs in the pediatric cancer center work collaboratively with community physicians to provide care for childhood cancer survivors. This type of shared care has been proposed as the optimal model to facilitate coordination between the cancer center oncology team and community physician groups providing survivor care.[70]
Sources: 70
An essential service of long-term follow-up programs is the organization of an individualized survivorship care plan that includes the following:
Details about therapeutic interventions undertaken for childhood cancer and their potential health risks (e.g., chemotherapy type and cumulative dose, radiation treatment fields and dose, surgical procedures, blood product transfusions, and HSCT).
Personalized health screening recommendations.
Information about lifestyle factors that modify risks.
A CCSS investigation that evaluated perceptions of future health and cancer risk highlighted the importance of continuing education of survivors during long-term follow-up evaluations. A substantial subgroup of adult survivors reported a lack of concern about future health (24%) and subsequent cancer risks (35%), even after exposure to treatments associated with increased risks. These findings present concerns that survivors may be less likely to engage in beneficial screenings and risk-reduction activities.[71]
Sources: 71
The CCSS evaluated the surveillance and screening practices of 11,337 childhood cancer survivors. They found that fewer than half of high-risk survivors at increased risk of developing SMNs or cardiac dysfunction received the recommended surveillance, which likely exposes them to preventable morbidity and mortality.[59]
Sources: 59
27% of survivors and 20% of primary care providers (PCP) had a survivorship care plan. Survivors treated after 1990 were more likely to have a survivorship care plan.
Survivorship care plan possession by high-risk survivors was associated with increased adherence to COG-recommended breast (22% vs. 8%), skin (35% vs. 23%), and cardiac (67% vs. 33%) surveillance. PCP survivorship care plan possession was associated with increased adherence to skin surveillance (40% vs. 23%).
Among high-risk survivors, adherence increased for colorectal (14% to 41%, P < .001) and cardiac (22% to 38%, P < .001) surveillance and decreased for breast surveillance (38% to 13%, P < .001) between 2007 and 2016.
For average-risk survivors, better adherence to American Cancer Society recommendations for breast (57%), cervical (84%), and colorectal (69%) screening was observed than with COG recommendations. PCP survivorship care plan possession was associated with increased adherence to breast and colorectal screening. Survivors were less adherent to breast screening than the general population and less adherent to cervical screening than siblings.
For survivors who have not been provided with this information, the COG offers a template that can be used by survivors to organize a personal treatment summary. For more information, see the COG Survivorship Guidelines, Appendix 1.
Sources: Survivorship Guidelines, Appendix 1
COG long-term follow-up guidelines for childhood and AYA cancer survivors
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
To facilitate survivor and provider access to succinct information to guide risk-based care, COG investigators have organized a compendium of exposure- and risk-based health surveillance recommendations, with the goal of standardizing the care of childhood cancer survivors.[72]
Sources: 72
The compendium of resources includes the following:
Long-Term Follow-Up Guidelines. COG Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers are appropriate for asymptomatic survivors presenting for routine exposure-based medical evaluation 2 or more years after completion of therapy.
Sources: Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers
Health Links. Patient education materials called Health Links provide detailed information on guideline-specific topics to enhance health maintenance and promotion among this population of cancer survivors.[73]
Sources: 73
Information concerning late effects is summarized in tables throughout this summary.
Several groups have undertaken research to evaluate the yield from risk-based screening as recommended by the COG and other pediatric oncology cooperative groups.[7,74,75] Pertinent considerations in interpreting the results of these studies include the following:
Variability in the cohort’s age at treatment.
Age at screening.
Time from cancer treatment.
Participation bias.
Collectively, these studies demonstrate that screening identifies a substantial proportion of individuals with previously unrecognized, treatment-related health complications of varying degrees of severity. Study results have also identified low-yield evaluations that have encouraged revisions of screening recommendations. Ongoing research is evaluating the cost effectiveness of screening in the context of consideration of benefits, risks, and harms.
Myelodysplastic Syndrome and Acute Myeloid Leukemia Postcytotoxic Therapy (MDS-pCT and AML-pCT)
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Subsequent primary leukemias have been reported in survivors of Hodgkin lymphoma, leukemia, sarcoma, CNS tumors, non-Hodgkin lymphoma, neuroblastoma, and Wilms tumor. In a cohort of nearly 70,000 5-year childhood cancer survivors, survivors had a fourfold increased risk (SIR, 3.7) of developing a leukemia, with an absolute excess risk of 7.5. Specifically, a sixfold relative risk of developing a myeloid leukemia (SIR, 5.8) was reported.[15]
Sources: 15
The risk remained significantly elevated beyond 20 years from the first primary malignancy (SIR, 2.4).
Hodgkin lymphoma survivors had the greatest excess risk of developing a subsequent leukemia (SIR, 7.9) and specifically a myeloid leukemia (SIR, 12.1), with the largest excess risk seen before 20 years of follow-up.
A pooled analysis examined all published studies with detailed treatment data for children with cancer diagnosed between 1930 and 2000. Treatment data included estimated radiation doses to the active bone marrow and doses of specific chemotherapy agents. In this report, 147 cases of second primary leukemia (69% of cases were AML) were matched to 522 controls.[16]
Sources: 16
After controlling for other therapies, topoisomerase II inhibitor therapy was associated with an increased risk of second AML (no radiation and >2,500 mg/m2 vs. none: OR, 14.3; 95% CI, 2.7–75.1).
Radiation dose to the active bone marrow was also associated with an increased risk of second AML among patients who did not receive chemotherapy (>0–12 Gy: OR, 4.9; 95% CI, 0.95–25.6) but not among those who received chemotherapy.
Second primary leukemias were most likely to occur in the first decade after cancer treatment.[17]
Sources: 17
A short latency (<10 years from primary cancer diagnosis). The risk of MDS-pCT or AML-pCT plateaus after 10 to 15 years. Although the risk of subsequent leukemia remains significantly elevated beyond 15 years from primary diagnosis (SIR, 3.5; 95% CI, 1.9–6.0), these events are relatively rare, with an absolute excess risk of 0.02 cases per 1,000 person-years.[19]
Sources: 19
An association with alkylating agents and/or topoisomerase II inhibitors.
Based on the updated definitions from the World Health Organization, MDS-pCT and AML-pCT are clonal disorders, which arise in patients previously exposed to cytotoxic therapy, either chemotherapy or large-field radiation therapy, for an unrelated neoplasm.[20] The following two types of MDS-pCT and AML-pCT are the most frequently observed among survivors:
Sources: 20
Alkylating agent–related type: Alkylating agents associated with MDS-pCT and AML-pCT include cyclophosphamide, ifosfamide, mechlorethamine, melphalan, busulfan, nitrosoureas, chlorambucil, and dacarbazine.[21] The risk of alkylating agent–related MDS or AML is dose dependent, with a latency of 3 to 5 years after exposure; it is associated with abnormalities involving chromosomes 5 (-5/del(5q)) and 7 (-7/del(7q)).[21]
Topoisomerase II inhibitor–related type: Topoisomerase II inhibitor agents include etoposide, teniposide, and anthracycline-related drugs.Most of the translocations observed in patients exposed to topoisomerase II inhibitors disrupt a breakpoint cluster region between exons 5 and 11 of the band 11q23 and fuse KMT2A with a partner gene.[21] Topoisomerase II inhibitor–related AML presents as overt leukemia after a latency of 6 months to 3 years and is associated with balanced translocations involving chromosome bands 11q23 or 21q22.[22]
For more information, see the Therapy-Related AML and Therapy-Related Myelodysplastic Neoplasms section in Childhood Acute Myeloid Leukemia Treatment.
Sources: Therapy-Related AML and Therapy-Related Myelodysplastic Neoplasms
Therapy-Related Solid SNs
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Therapy-related solid SNs represent 80% of all SNs, demonstrate a strong relationship with radiation exposure, and are characterized by a latency that exceeds 10 years. The risk of solid SNs continues to increase with longer follow-up. The risk of solid SNs is highest when the following occur:[4,13]
Younger age at time of radiation exposure.
High total dose of radiation.
Longer period of follow-up after radiation exposure.
The histological subtypes of solid SNs encompass a neoplastic spectrum ranging from benign and low-grade malignant lesions (e.g., NMSC, meningiomas) to high-grade malignancies (e.g., breast cancers, glioblastomas) (see Figure 4).[4,13,23,24]
Solid SNs in childhood cancer survivors most commonly involve the following:[4,13,23,25-28]
Breast.
Sources: Breast
Thyroid.
Sources: Thyroid
CNS.
Sources: CNS
Bone and soft tissue.
Sources: Bone and soft tissue
Skin.
Sources: Skin
With longer follow-up of adult survivors of childhood cancer cohorts, epithelial neoplasms have been observed in the following:[13,29]
Lung.
Sources: Lung
Gastrointestinal tract.
Sources: Gastrointestinal tract
Oral cavity.
Sources: Oral cavity
Genitourinary system.
Sources: Genitourinary system
Kidney.
Sources: Kidney
Subsequent neoplasms after hematopoietic stem cell transplant (HSCT)
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Recipients of HSCT are treated with high-dose chemotherapy and, often, TBI, which makes their risk of SNs unique from that of the general oncology population.
Among 4,318 first-time allogeneic HSCT recipients treated for AML and chronic myeloid leukemia between 1986 and 2005, and conditioned with high-dose busulfan and cyclophosphamide (Bu-Cy), 66 solid cancers were reported at a median of 6 years post-HSCT.[31]
Sources: 31
Among 4,318 first-time allogeneic HSCT recipients treated for AML and chronic myeloid leukemia between 1986 and 2005, and conditioned with high-dose busulfan and cyclophosphamide (Bu-Cy), 66 solid cancers were reported at a median of 6 years post-HSCT.[31]
The cumulative incidence of new solid cancers was 0.9% at 5 years and 2.4% at 10 years and appears to be similar, regardless of exposure to radiation.
Bu-Cy conditioning without TBI was associated with higher risks of solid SNs than in the general population.
Chronic graft-versus-host disease increased the risk of SNs, especially those involving the oral cavity.
A study of 4,905 1-year survivors of allogeneic HSCT who underwent transplant between 1969 and 2014 for malignant or nonmalignant diseases, and were followed for a median 12.5 years, demonstrated a strong effect of TBI dose and dose fractionation on risk of SNs.[32]
Sources: 32
A study of 4,905 1-year survivors of allogeneic HSCT who underwent transplant between 1969 and 2014 for malignant or nonmalignant diseases, and were followed for a median 12.5 years, demonstrated a strong effect of TBI dose and dose fractionation on risk of SNs.[32]
The 20-year cumulative incidence of SN after HSCT for individuals treated at younger than 20 years was 8.1%.
SN risk was highest in survivors exposed to high-dose, single-fraction TBI (6–12 Gy) or very high-dose fractionated TBI (14.4–17.5 Gy).
With low-dose TBI (2–4.5 Gy), the SN risk was comparable to the risk with chemotherapy alone, although it was still twofold higher than in the general population.
Among individuals treated at younger than 20 years, the number of SNs was 12.5-fold higher than expected in the general population, and the excess absolute risk was 10.6 per 1,000 person-years. Survivors treated with HSCT at this young age were more likely to develop SNs than were survivors who were treated after age 50 years (HR, 2.3).
Some well-established solid SNs are described in the following sections.
Breast cancer
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Female survivors of childhood, adolescent, and young adult cancer treated with radiation therapy to fields including the chest are at increased risk of developing breast cancer.
The cumulative breast cancer incidence ranges from 8% to 20% by age 40 to 45 years among childhood cancer survivors and is as high as 35% by age 50 years in Hodgkin lymphoma survivors, comparable to that observed among BRCA gene variant carriers.[18,33-36]
Radiation dose and volume of breast exposed are important factors affecting risk. Specific chemotherapeutic agents, particularly alkylating agents and anthracyclines, may affect risk as well.[33,35,37]
Evidence (excess risk of breast cancer):
Breast cancer is the most common therapy-related solid SN after a previous diagnosis of Hodgkin lymphoma.[18,34] The following has been observed in female survivors of childhood Hodgkin lymphoma:
Breast cancer is the most common therapy-related solid SN after a previous diagnosis of Hodgkin lymphoma.[18,34] The following has been observed in female survivors of childhood Hodgkin lymphoma:
Excess risk of breast cancer has been reported in survivors treated with high-dose, extended-volume radiation at age 30 years or younger.[38]
Sources: 38
Data indicate that females treated with low-dose, involved-field radiation also exhibit excess breast cancer risk.[39]
Sources: 39
Patients who received limited volume supradiaphragmatic radiation therapy (excluding the axillae) had a significantly lower risk of subsequent breast cancers than patients who received full mantle-field radiation therapy.[37]
Sources: 37
For patients treated with radiation therapy to the chest before age 16 years, the cumulative incidence of breast cancer approaches 20% by age 45 years.[18]
Sources: 18
The latency period after chest irradiation ranges from 8 to 10 years, and the risk of subsequent breast cancer increases in a linear fashion with radiation dose (P for trend < .001).[40]
Sources: 40
Treatment with higher cumulative doses of alkylating agents and ovarian radiation of 5 Gy or higher (exposures predisposing to premature menopause) have been correlated with reductions in breast cancer risk, underscoring the potential contribution of hormonal stimulation on breast carcinogenesis.[37,41,42]
The observed number of invasive breast cancer cases among young (aged <30 years) survivors, compared with what is expected in the general population, has decreased over recent treatment eras (1970s SIR, 55.0 vs. 1990s SIR, 14.3).[36]
Sources: 36
The risk of breast cancer was also increased in the following studies that used lower radiation doses to treat cancer that metastasized to the chest/lung (e.g., Wilms tumor, sarcoma) and exposed the breast tissue:
The risk of breast cancer was also increased in the following studies that used lower radiation doses to treat cancer that metastasized to the chest/lung (e.g., Wilms tumor, sarcoma) and exposed the breast tissue:
In 116 children in the CCSS cohort treated with 2 Gy to 20 Gy to the lungs (median, 14 Gy), the SIR for breast cancer was 43.6 (95% CI, 27.1–70.1).[35]
Sources: 35
A report of 2,492 female participants in the National Wilms Tumor Studies 1 through 4 (1969–1995) addressed the excess risk of breast cancer.[43]
Sources: 43
The risk of breast cancer was also increased in the following studies that used lower radiation doses to treat cancer that metastasized to the chest/lung (e.g., Wilms tumor, sarcoma) and exposed the breast tissue: › A report of 2,492 female participants in the National Wilms Tumor Studies 1 through 4 (1969–1995) addressed the excess risk of breast cancer.[43]
Sixteen of 369 women who received chest irradiation for metastatic Wilms tumor developed invasive breast cancer (cumulative risk at age 40 years, 14.8% [95% CI, 8.7%–24.5%]). The SIR of 27.6 (95% CI, 16.1–44.2) was based on 5,010 person-years of follow-up.
Of the 369 patients, radiation doses to the chest were less than 12 Gy in 4%, 12 Gy in 64%, 13 Gy to 15 Gy in 19%, and more than 15 Gy in 13% of patients.
For all patients who developed breast cancer (with or without chest irradiation), the median age at first breast cancer diagnosis was 34.3 years (range, 15.5–48.4) and the median time from Wilms tumor diagnosis was 27.1 years (range, 7.9–35.7).
An international collaborative study pooled individual patient data from 17,903 childhood cancer survivors. The study evaluated the dose-dependent effects of individual anthracycline agents on the development of subsequent breast cancer and interactions with chest radiation therapy. There were 782 survivors (4.4%) who developed a subsequent breast cancer.[44]
Sources: 44
An international collaborative study pooled individual patient data from 17,903 childhood cancer survivors. The study evaluated the dose-dependent effects of individual anthracycline agents on the development of subsequent breast cancer and interactions with chest radiation therapy. There were 782 survivors (4.4%) who developed a subsequent breast cancer.[44]
Doxorubicin was associated with a dose-dependent increase of subsequent breast cancer risk (HR per 100 mg/m2, 1.24; 95% CI, 1.18–1.31).
There was a more-than-twofold increased risk for survivors treated with 200 mg/m2 or higher cumulative doxorubicin dose, compared with no doxorubicin (HR, 2.50 for 200–299 mg/m2; HR, 2.33 for 300–399 mg/m2; HR, 2.78 for ≥400 mg/m2).
The associations were not statistically significant for daunorubicin, whereas epirubicin was associated with increased subsequent breast cancer risk (exposure yes vs. no: HR, 3.25; 95% CI, 1.59–6.63).
The HRs per 100 mg/m2 of doxorubicin were 1.11 (95% CI, 1.02–1.21) for patients treated with chest radiation therapy and 1.26 (95% CI, 1.17–1.36) for patients who did not receive chest radiation therapy.
The risk of developing breast cancer after radiation therapy and chemotherapy with anthracyclines was evaluated in the CCSS. In a nested-case control study of 271 childhood cancer survivors (diagnosed between 1970–1986) who were subsequently diagnosed with breast cancer, the combination of anthracyclines and radiation therapy to the breast was associated with increased risks of breast cancer consistent with an additive interaction.[33]
Sources: 33
The risk of developing breast cancer after radiation therapy and chemotherapy with anthracyclines was evaluated in the CCSS. In a nested-case control study of 271 childhood cancer survivors (diagnosed between 1970–1986) who were subsequently diagnosed with breast cancer, the combination of anthracyclines and radiation therapy to the breast was associated with increased risks of breast cancer consistent with an additive interaction.[33]
For the study group, the median age of first cancer diagnosis was 15 years and the median age at breast cancer diagnosis was 39 years.
The OR for breast cancer increased with increasing radiation dose to the breast (OR per 10 Gy, 3.9; 95% CI, 2.5–6.5) and was similar for estrogen receptor–positive and estrogen receptor–negative cancers.
The OR per 10 Gy to the breast was higher for women who received ovarian doses less than 1 Gy (OR, 6.8; 95% CI, 3.9–12.5) than for women who received ovarian doses greater than or equal to 15 Gy (OR, 1.4; 95% CI, 1.0–6.4).
The OR for breast cancer increased with cumulative anthracycline dose (OR per 100 mg/m2, 1.23; 95% CI, 1.09–1.39; P < .01 for trend).
There was an additive interaction between radiation therapy and anthracycline treatment. The OR was 19.1 (95% CI, 7.6–48.0) for the combined association of anthracycline therapy and breast radiation dose of 10 Gy or more (compared with 0 to less than 1 Gy) versus 9.6 (95% CI, 4.4–20.7) without anthracycline therapy.
Childhood cancer survivors not exposed to chest radiation also have an increased risk of breast cancer at a young age.
Childhood cancer survivors not exposed to chest radiation also have an increased risk of breast cancer at a young age.
The SJLIFE study assessed subsequent breast cancer risk among 1,467 female cancer survivors and evaluated risk associated with anthracycline exposure. The study also evaluated whether surveillance imaging affects breast cancer outcomes.[25]
Sources: 25
Childhood cancer survivors not exposed to chest radiation also have an increased risk of breast cancer at a young age. › The SJLIFE study assessed subsequent breast cancer risk among 1,467 female cancer survivors and evaluated risk associated with anthracycline exposure. The study also evaluated whether surveillance imaging affects breast cancer outcomes.[25]
In women who received neither chest radiation nor anthracyclines, the cumulative incidence of breast cancer was 2% at age 35 years and 15% at age 50 years. For women who were treated with 250 mg/m2 or higher of anthracyclines, the rates were 7% at age 35 years and 46% at age 50 years.
Anthracycline doses of 250 mg/m2 or higher remained significantly associated with increased risk of breast cancer in models, excluding survivors with cancer predisposition gene variants, chest radiation of 10 Gy or higher, or both.
Breast cancers detected by imaging and/or prophylactic mastectomy were more likely to be in situ carcinomas, be smaller masses, have no lymph node involvement, and be treated without chemotherapy, compared with breast cancers detected by physical findings.
Dual imaging with mammography and breast magnetic resonance imaging (MRI) in this cohort was a sensitive and specific approach to identify breast cancers that require less aggressive therapy than breast cancers detected by physical findings.
Childhood cancer survivors not exposed to chest radiation also have an increased risk of breast cancer at a young age.
A CCSS investigation examined the breast cancer risk of 3,768 female participants who did not receive chest radiation.[45]
Sources: 45
Childhood cancer survivors not exposed to chest radiation also have an increased risk of breast cancer at a young age. › A CCSS investigation examined the breast cancer risk of 3,768 female participants who did not receive chest radiation.[45]
A fourfold excess risk (SIR, 4.0; 95% CI, 3.0–5.3) of breast cancer was observed compared with rates in the general population.
Breast cancer risk was highest among survivors of sarcoma (SIR, 5.3; 95% CI, 3.6–7.8) and leukemia (SIR, 4.1; 95% CI, 2.4–6.9), for whom the cumulative incidence of breast cancer was estimated to be 5.8% and 6.3%, respectively, by age 45 years.
Treatment with alkylating agents and anthracyclines increased the risk of breast cancer in a dose-dependent manner.
Childhood cancer survivors not exposed to chest radiation also have an increased risk of breast cancer at a young age.
CCSS investigators also examined SN risk among 7,448 participants who were treated with chemotherapy only.[12]
Sources: 12
Childhood cancer survivors not exposed to chest radiation also have an increased risk of breast cancer at a young age. › CCSS investigators also examined SN risk among 7,448 participants who were treated with chemotherapy only.[12]
Breast cancer incidence was 4.6-fold greater than what would be expected in the general population (SIR, 4.6; 95% CI, 3.5–6.0).
A linear dose response was demonstrated between anthracyclines and breast cancer rate (RR, 1.3/100 mg/m2; 95% CI, 1.2–1.6).
Childhood cancer survivors not exposed to chest radiation also have an increased risk of breast cancer at a young age.
DCOG-LATER investigators evaluated the contribution of chemotherapy to solid cancer risk in a large cohort of childhood cancer survivors diagnosed between 1963 and 2001.[13]
Sources: 13
Childhood cancer survivors not exposed to chest radiation also have an increased risk of breast cancer at a young age. › DCOG-LATER investigators evaluated the contribution of chemotherapy to solid cancer risk in a large cohort of childhood cancer survivors diagnosed between 1963 and 2001.[13]
Survivors treated with doxorubicin exhibited a dose-dependent increased risk of breast cancer (HR, 3.1; 95% CI, 1.4–6.5 among survivors treated with anthracycline doses of 250 mg/m2 or higher).
The doxorubicin–breast cancer dose response was stronger for survivors of Li-Fraumeni–associated cancers (leukemia, CNS, and sarcomas other than Ewing) than for survivors of other cancers.
A SEER Program–based study evaluated trends in surgical management and the 5- and 10-year cumulative incidence of contralateral breast cancer among women who were treated with radiation therapy for Hodgkin lymphoma before age 30 years and diagnosed with a subsequent breast cancer between 1990 and 2016.[46]
Sources: 46
A SEER Program–based study evaluated trends in surgical management and the 5- and 10-year cumulative incidence of contralateral breast cancer among women who were treated with radiation therapy for Hodgkin lymphoma before age 30 years and diagnosed with a subsequent breast cancer between 1990 and 2016.[46]
Overall, 263 (89.2%) women presented with unilateral breast cancer, 50 of whom (19.0%) underwent breast-conserving surgery and 213 of whom (81.0%) underwent mastectomy (40.5% bilateral).
The 5-year incidence of contralateral breast cancer in women who underwent unilateral surgery was 9.4% (95% CI, 5.6%–15.4%), increasing to 20.2% (95% CI, 13.7%–29.2%) at 10 years and 29.9% (95% CI, 20.8%–41.9%) at 15 years. This finding underscores the importance of ongoing breast cancer surveillance and consideration of prophylactic mastectomy.
Breast cancer risk varies among childhood cancer survivors who are treated with chest radiation therapy, and the risk is based on multiple clinical factors. The first personalized breast cancer risk prediction model was developed and validated using multinational cohorts of female 5-year cancer survivors who were diagnosed at younger than 21 years and treated with chest irradiation (n = 2,147). The model includes current age, chest radiation field, whether chest radiation was delivered within 1 year of menarche, anthracycline exposure, age of menopause, and history of a first-degree relative with breast cancer. The model is available as an online risk calculator.[47]
Sources: online risk calculator · 47
Subsequent versus de novo breast cancer
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Several studies have investigated the clinical characteristics of subsequent breast cancers arising in women treated with radiation therapy for childhood cancer.[48-52]
In one population-based study, radiation-induced breast cancer was noted to have more adverse clinicopathological features, as evidenced by a twofold increased risk of estrogen receptor–negative, progesterone receptor–negative breast cancer observed among 15-year Hodgkin lymphoma survivors, compared with women who had sporadic breast cancer.[48]
Sources: 48
Other studies have observed a higher proportion of more histologically aggressive subtypes (e.g., triple-negative breast cancer) than age-matched sporadic invasive cancers.[49,50]
These findings are in contrast to other smaller, hospital-based, case-control studies of breast cancer among Hodgkin lymphoma survivors that have not identified a significant variation in hormone receptor status when compared with primary breast cancer controls. Previous studies have also not demonstrated a significant difference in overall risk of high-grade versus low-grade tumors.[51,52]
A study using SEER Program data evaluated the clinicopathological features of 321 breast cancers diagnosed in 257 women (median age, 22 years; range, 18–26 years at Hodgkin lymphoma diagnosis) who were previously treated with radiation for Hodgkin lymphoma.[53]
Sources: 53
A study using SEER Program data evaluated the clinicopathological features of 321 breast cancers diagnosed in 257 women (median age, 22 years; range, 18–26 years at Hodgkin lymphoma diagnosis) who were previously treated with radiation for Hodgkin lymphoma.[53]
Women who developed breast cancer after radiation for Hodgkin lymphoma were younger than women diagnosed with breast cancer without a prior malignancy (43 vs. 60 years) and were less likely to present with ductal carcinoma in situ (0.4% vs. 14.9%).
Radiation was not associated with poorer biological features, compared with breast cancers diagnosed in similarly aged women with no prior malignancy. However, higher proportions of upper outer quadrant and smaller tumors (≤2 cm) were found.
Most tumors in survivors of Hodgkin lymphoma were hormone sensitive (nearly two-thirds were estrogen receptor–positive/HER2-negative). This finding suggests that endocrine prevention may be an option for this high-risk population.
Mortality after subsequent breast cancer
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
In a study of female participants in the CCSS who were subsequently diagnosed with breast cancer (n = 274) and matched to a control group of women (n = 1,095) with de novo breast cancer, the following was observed:[54]
Sources: 54
Survivors of childhood cancer were found to have elevated mortality rates (HR, 2.2; 95% CI, 1.7–3.0), even after adjusting for breast cancer treatment.
Survivors were five times more likely to die from other health-related causes, including other SMNs and cardiovascular or pulmonary disease (HR, 5.5; 95% CI, 3.4–9.0).
The cumulative incidence of a second asynchronous breast cancer was elevated significantly compared with controls (at 5 years, 8.0% among childhood cancer survivors vs. 2.7% among controls; P < .001).
Although current evidence does not show a survival benefit from the initiation of breast cancer surveillance in women treated with radiation therapy to the chest for childhood cancer, interventions to promote detection of small and early-stage tumors may improve prognosis. Those with more limited treatment options because of previous exposure to radiation or anthracyclines may especially benefit.
In support of surveillance, SJLIFE investigators observed that breast cancers detected by imaging and/or prophylactic mastectomy were more likely to be in situ carcinomas, be smaller masses (3.3 cm mean tumor size detected by physical examination vs. 1.1 cm detected by imaging), have no lymph node involvement, and be treated without chemotherapy, compared with breast cancers detected by physical findings.[25]
Sources: 25
Investigators used data from the CCSS and two Cancer Intervention and Surveillance Modeling Network breast cancer simulation models to estimate the clinical benefits, harms, and cost-effectiveness of breast cancer screening among childhood cancer survivors who were previously treated with chest radiation.[55]
Sources: 55
Screening with mammography and MRI, as recommended in COG Long-Term Follow-Up guidelines, is projected to avert half of the expected breast cancer deaths among high-risk survivors.
On an annual schedule, a survivor will have an average of 4 to 5 false-positive screening results and 1 to 2 benign biopsy results over the course of their lifetime.
Because of the large survival benefits, the harm-benefit tradeoffs for survivors were found to be appropriate, resulting in more favorable harm-benefit ratios.
Another CCSS investigation quantified the association between temporal changes in cancer treatment over three decades and subsequent breast cancer risk.[36]
Sources: 36
The cumulative incidence of breast cancer was 8.1% (95% CI, 7.3%–9.0%) by age 45 years among 11,550 female survivors (median age, 34.2 years), representing a more than sixfold excess risk (SIR, 6.6; 95% CI, 6.1–7.2), compared with age-, sex-, and calendar year–matched controls.
Concurrent with changes in therapy by decade, including reduced rates of chest and pelvic radiation therapy and increased rates of anthracycline chemotherapy exposure, and adjusting for age and age at diagnosis, the invasive breast cancer rate decreased 18% for every 5 years of primary cancer diagnosis era (rate ratio, 0.82; 95% CI, 0.74–0.90). This finding was largely associated with the reduced rate of chest radiation therapy.
Thyroid cancer
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Neck radiation therapy for Hodgkin lymphoma, acute lymphoblastic leukemia (ALL), and brain tumors.
Iodine I 131-metaiodobenzylguanidine (131I-MIBG) treatment for neuroblastoma.
TBI for HSCT.
Chemotherapy only, without therapeutic radiation.
The 25-year cumulative incidence of thyroid cancer among survivors of childhood cancer is 0.5%.[13] The risk of thyroid cancer among childhood cancer survivors is more than tenfold higher than that of the general population (SIR, 10.5; 95% CI, 9.1–12).[4] Significant modifiers of the radiation-related risk of thyroid cancer include the following:[28,58]
Female sex.
Younger age at exposure.
Longer time since exposure.
Radiation dose. A linear dose-response relationship between radiation exposure and thyroid cancer is observed up to 10 Gy, with a leveling off between 10 Gy and 30 Gy, and a decline in the OR at higher doses, especially in children younger than 10 years at treatment, suggesting a cell killing effect of the target cells at higher doses.[24,28,59]
In a Dutch case-control study, childhood cancer survivors with subsequent thyroid cancer were more likely to present with smaller tumors and bilateral tumors than the general population. Treatment outcomes were similar between subsequent and sporadic thyroid cancers.[60]
Sources: 60
For information about detecting thyroid nodules and thyroid cancer, see the Thyroid nodules section.
Sources: Thyroid nodules
CNS tumors
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Subsequent CNS tumors represent a spectrum of histological subtypes, from high-grade gliomas to benign meningiomas. A comprehensive Pediatric Normal Tissue Effects in the Clinic (PENTEC) review analyzed the risk of SNs. The study reported a 10-year median latency period for the development of a malignant CNS neoplasm and a 21-year median latency period for the development of a meningioma.[61] Accurate assessment of the prevalence of low-grade and benign lesions is challenging because of the variable opinions and practices related to neuroimaging versus symptom surveillance in long-term survivors treated with cranial irradiation. Therefore, the prevalence of these tumors is likely higher than proven.
Sources: 61
Brain tumors develop after cranial irradiation for histologically distinct brain tumors or for management of disease among ALL or non-Hodgkin lymphoma patients.[62] SIRs reported for subsequent CNS neoplasms after treatment for childhood cancer range from 8.1 to 52.3 across studies.[24]
The risk of subsequent brain tumors demonstrates a linear relationship with radiation dose.[26,61,63]
The risk of meningioma after radiation increases with radiation dose,[9,61] and in some studies is further potentiated with increased exposure to intrathecal methotrexate.[26] However, this finding has not been consistently replicated.[10]
Cavernomas have also been reported with considerable frequency after CNS irradiation but have been speculated to result from angiogenic processes as opposed to true tumorigenesis.[64-66]
The Dutch Long-Term Effects after Childhood Cancer (LATER) investigators have described the clinical characteristics of childhood cancer survivors who developed histologically confirmed meningiomas.[11]
Sources: 11
In 6,015 childhood cancer survivors from the LATER cohort, 1,551 of whom had prior cranial radiation therapy, 93 survivors developed meningiomas.
Of these patients, 89 (95.7%) were treated with prior cranial radiation therapy. The median age at diagnosis was 31.8 years (range, 13.2–50.5 years).
Thirty of the survivors presented with synchronous meningiomas, and 84 survivors presented with symptoms. Only 16% of the meningiomas were detected in late effects clinics.
All survivors underwent surgery, and one-third (n = 31) of them also received radiation therapy. Twelve survivors had three or more surgeries for growth of residual tumor, recurrences, and new meningiomas. Although the extent of surgical resection was not described, the indications for radiation therapy during follow-up after surgical resection included residual tumor, recurrences, location, or new meningioma. During follow-up, 38 survivors (40.9%) developed new meningiomas, 22 (23.7%) had recurrences, and at least 4 died because of the meningioma.
The European PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies (PanCareSurFup) investigators described findings in childhood cancer survivors who developed meningiomas or gliomas:[67]
Sources: 67
In 69,460 survivors, 279 developed gliomas, and 761 developed meningiomas.
Gliomas and meningiomas were most frequently observed after any CNS tumor or leukemia, accounting for more than 70% of all observed gliomas and 80% of all meningiomas.
Among patients with known cranial radiation status who developed a glioma, 61% had received prior cranial radiation therapy. Among patients who developed a meningioma, 64.7% had received cranial radiation therapy.
CNS tumor survivors treated with cranial radiation therapy were at the highest risk of developing gliomas, at 27 times the risk of the general population (95% CI, 21.5–33.2). CNS tumor survivors who did not receive cranial radiation were at 8.3 times the risk of the general population (95% CI, 4.9–14.1).
Among CNS tumor survivors, the relative risk for patients who received cranial radiation therapy was 13 times the risk for patients who did not receive cranial radiation therapy (95% CI, 6.7–25.4). Among leukemia survivors, those who received cranial radiation therapy were at a 5-fold increased risk compared with those treated without cranial radiation therapy (95% CI, 2.9–9.9).
A PENTEC analysis of CNS SNs included 32 published studies of 1,035 subsequent meningiomas after previous radiation therapy in childhood cancer survivors.[61]
Sources: 61
A significant dose-response relationship was reported for CNS subsequent meningiomas (excess relative ratio [ERR]/Gy, 0.44).
Younger age at the time of primary diagnosis was associated with a higher risk of subsequent meningiomas.
Females had a higher risk of subsequent meningiomas than males (odds ratio, 1.46; P < .0001).
Median latency time to the development of meningiomas was 21 years.
Neurological sequelae associated with meningiomas can include seizures, auditory-vestibular-visual deficits, focal neurological dysfunction, and severe headaches.[9] Despite the well-established increased risk of subsequent CNS neoplasms among childhood cancer survivors treated with cranial irradiation and the growing recognition of associated morbidity, the current literature is insufficient to evaluate the potential harms and benefits of routine screening for these lesions.[68] The decision to initiate surveillance should be shared by the cancer survivor and health care provider after carefully considering the potential harms and benefits of surveillance for CNS neoplasms, such as meningioma.
Proton radiation therapy for pediatric medulloblastoma is associated with low rates of brain stem injury and secondary malignancies. The long-term effects were reported in 178 pediatric patients with medulloblastoma who were treated with surgery, proton radiation therapy, and chemotherapy between 2002 and 2016 (median follow-up, 9.3 years).[69]
Sources: 69
At 10 years, eight patients (4.5%) developed a secondary tumor (benign or malignant), with median follow up of 9.1 years. Three patients (1.7%) developed a secondary malignancy.
In-field second malignancies were glioblastoma (n = 2), meningioma (n = 2), and high-grade glioma (n = 1). The other malignancies were one each of ovarian fibroma, plexiform fibromyxoma of the esophagus, and papillary thyroid carcinoma.
Four patients developed brain stem injury at a median of 4.2 years. The 5-year cumulative incidence of brain stem injury was 1.1%, and the 10-year cumulative incidence was 1.9%.
Bone and soft tissue tumors
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Survivors of hereditary retinoblastoma, Ewing sarcoma, and other malignant bone tumors are at a particularly increased risk of developing subsequent bone and soft tissue tumors.[70-74]
In a PENTEC investigation on subsequent malignancies, the estimated pooled ERR/Gy for subsequent sarcomas was 0.045. There was a possible biphasic dose response, with higher rates of relapse and subsequent sarcomas above 55 Gy. After 20 Gy and anthracyclines, the absolute excess risk is predicted to be 0.24% at 50 years and 0.86% at 75 years. The median latency time to the development of sarcomas was 11 years (range, 4–23 years).[61]
Sources: 61
After adjustment for radiation therapy, treatment with alkylating agents [13,61] and anthracyclines [77] have both been linked to sarcoma, with the risk increasing with cumulative drug exposure.[77]
Soft tissue sarcomas can be of various histological subtypes, including nonrhabdomyosarcoma soft tissue sarcomas, rhabdomyosarcoma, malignant peripheral nerve sheath tumors, Ewing/primitive neuroectodermal tumors, and other rare tumor types.
Evidence (excess risk of bone and soft tissue tumors):
A nested case-control study included 228 cases and 228 matched controls within a cohort of 69,460 5-year survivors of childhood cancer. The study investigated the risks of subsequent primary bone cancer by different levels of cumulative radiation exposure and dose-response relationships according to different specific types of chemotherapy.[78]
Sources: 78
A nested case-control study included 228 cases and 228 matched controls within a cohort of 69,460 5-year survivors of childhood cancer. The study investigated the risks of subsequent primary bone cancer by different levels of cumulative radiation exposure and dose-response relationships according to different specific types of chemotherapy.[78]
Compared with unexposed bone tissue, the OR associated with bone tissue exposed to 1 to 4 Gy was 4.8-fold (95% CI, 1.2–19.6). The OR associated with bone tissue exposed to 5 to 9 Gy was 9.6-fold (95% CI, 2.4–37.4). The OR increased linearly with increasing doses of radiation (Ptrend < .001), up to 78-fold (95% CI, 9.2–669.9) for doses of 40 Gy or higher.
For cumulative alkylating agent doses of 10,000 to 19,999 mg/m2 and 20,000 mg/m2 or higher, the radiation-adjusted ORs were 7.1 (95% CI, 2.2–22.8) and 8.3 (95% CI, 2.8–24.4), respectively. There were independent contributions from exposure to procarbazine, ifosfamide, or cyclophosphamide.
A population-based study of 69,460 5-year survivors of cancer diagnosed before age 20 years observed the following:[71,72]
A population-based study of 69,460 5-year survivors of cancer diagnosed before age 20 years observed the following:[71,72]
The risk of subsequent primary bone cancer was 22-fold greater than that of the general population, with an estimated 45-year cumulative incidence of 0.6%, compared with an expected rate of 0.03% in the general population.[71]
Sources: 71
The observed excess numbers of subsequent primary bone cancer declined with both age and years from diagnosis.[71]
Sources: 71
The risk of subsequent soft tissue sarcoma was almost 16-fold higher than the general population, with an estimated 45-year cumulative incidence of 1.4%, compared with an expected rate of 0.1%.[72]
Sources: 72
The median time from diagnosis to occurrence of a soft tissue sarcoma was 19 years.[72]
Sources: 72
The most commonly observed soft tissue sarcomas were leiomyosarcoma, fibromatous neoplasms, and malignant peripheral nerve sheath tumors.[72]
Sources: 72
The SIR for subsequent fibromatous primary sarcomas decreased with increasing years from diagnosis and attained age, whereas the SIR for leiomyosarcoma and malignant peripheral nerve sheath tumors remained consistently high across all years from diagnosis and at all attained ages.[72]
Sources: 72
The absolute excess risks of all sarcoma subtypes were generally low, except for leiomyosarcoma that followed a retinoblastoma diagnosis (absolute excess risks, 52.7 per 10,000 person-years among survivors 45 years or more from diagnosis).[72]
Sources: 72
The risk of developing a leiomyosarcoma was 30-fold higher among survivors of childhood cancer, compared with an excess risk of 0.7 for the general population.[72]
Sources: 72
A population-based study of 69,460 5-year survivors of cancer diagnosed before age 20 years observed the following:[71,72] › The risk of developing a leiomyosarcoma was 30-fold higher among survivors of childhood cancer, compared with an excess risk of 0.7 for the general population.[72]
Retinoblastoma survivors were at the highest risk (SIR, 342.9), followed by Wilms tumor survivors (SIR, 74.2).
90% of leiomyosarcomas observed after a Wilms tumor diagnosis developed within the irradiated tissue.
In a CCSS cohort, an increased risk of subsequent bone or soft tissue sarcoma was associated with radiation therapy, a primary diagnosis of sarcoma, a history of other SNs, and treatment with higher doses of anthracyclines or alkylating agents.[27]
Sources: 27
In a CCSS cohort, an increased risk of subsequent bone or soft tissue sarcoma was associated with radiation therapy, a primary diagnosis of sarcoma, a history of other SNs, and treatment with higher doses of anthracyclines or alkylating agents.[27]
The 30-year cumulative incidence of subsequent sarcoma in CCSS participants was 1.08% for survivors who received radiation therapy and 0.5% for survivors who did not receive radiation therapy.
Dose-risk modeling was used to study the risk of bone sarcoma in a retrospective cohort of 4,171 survivors of a childhood solid cancer treated between 1942 and 1986 (median follow-up, 26 years).[75]
Sources: 75
Dose-risk modeling was used to study the risk of bone sarcoma in a retrospective cohort of 4,171 survivors of a childhood solid cancer treated between 1942 and 1986 (median follow-up, 26 years).[75]
Results demonstrated that the risk of bone sarcoma increased slightly up to a cumulative organ-absorbed radiation dose of 15 Gy (HR, 8.2; 95% CI, 1.6–42.9) and then rapidly increased for higher radiation doses (HR for 30 Gy or more, 117.9; 95% CI, 36.5–380.6), compared with patients not treated with radiation therapy.
The excess RR per Gy in this model was 1.77 (95% CI, 0.62–5.94).
In survivors of bilateral retinoblastoma, the most commonly observed malignant SN is sarcoma, specifically osteosarcoma.[79-81] The contribution of chemotherapy to solid malignancy carcinogenesis was highlighted in a long-term follow-up study of 906 5-year hereditary retinoblastoma survivors who were diagnosed between 1914 and 1996 and observed through 2009.[70]
In survivors of bilateral retinoblastoma, the most commonly observed malignant SN is sarcoma, specifically osteosarcoma.[79-81] The contribution of chemotherapy to solid malignancy carcinogenesis was highlighted in a long-term follow-up study of 906 5-year hereditary retinoblastoma survivors who were diagnosed between 1914 and 1996 and observed through 2009.[70]
Treatment with alkylating agents significantly increased risk of subsequent bone tumors (HR, 1.60; 95% CI, 1.03–2.49) and leiomyosarcoma (HR, 2.67; 95% CI, 1.22–5.85) among members of the cohort.
Leiomyosarcoma occurrence was more common after treatment with alkylating agent chemotherapy and radiation therapy compared with radiation therapy alone (5.8% vs. 1.6% at age 40 years; P = .01).
The CCSS reported the following on 105 cases and 422 matched controls in a nested case-control study of 14,372 childhood cancer survivors:[77]
Sources: 77
The CCSS reported the following on 105 cases and 422 matched controls in a nested case-control study of 14,372 childhood cancer survivors:[77]
Soft tissue sarcomas occurred at a median of 11.8 years (range, 5.3–31.3 years) from original diagnoses.
Any exposure to radiation was associated with increased risk of soft tissue sarcoma (OR, 4.1; 95% CI, 1.8–9.5), which demonstrated a linear dose-response relationship.
Anthracycline exposure was associated with soft tissue sarcoma risk (OR, 3.5; 95% CI, 1.6–7.7), independent of radiation dose.
In a cohort of 952 irradiated survivors of hereditary retinoblastoma diagnosed between 1914 and 2006, CCSS investigators observed that elevated bone and soft tissue sarcoma risks differed by age, location, and sex.[81]
Sources: 81
In a cohort of 952 irradiated survivors of hereditary retinoblastoma diagnosed between 1914 and 2006, CCSS investigators observed that elevated bone and soft tissue sarcoma risks differed by age, location, and sex.[81]
Head and neck bone and soft tissue sarcomas were diagnosed beginning in early childhood and continued well into adulthood (60-year cumulative incidence of 6.8% and 9.3%, respectively).
Body and extremity bone sarcoma incidence flattened after adolescence (60-year cumulative incidence, 3.5%).
Body and extremity soft tissue sarcoma incidence was rare until age 30 years, when incidence rose steeply (60-year cumulative incidence, 6.6%) particularly for females (60-year cumulative incidence, 9.4%).
In a retrospective study of 160 patients with hereditary retinoblastoma who received radiation therapy, no correlation was identified between age (before or after 12 months) at which external-beam radiation therapy was given and development of subsequent malignancy.[73]
Sources: 73
In a retrospective study of 160 patients with hereditary retinoblastoma who received radiation therapy, no correlation was identified between age (before or after 12 months) at which external-beam radiation therapy was given and development of subsequent malignancy.[73]
Patients with and without subsequent malignancies did not differ by RB1 variant type. Also, there was no association with variant type and location of SMN, or SMN type and age at diagnosis.
The study showed that patients who have a low penetrance variant and receive external-beam radiation therapy remain at risk of SMNs and should be cautiously monitored.
Skin cancer
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Keratinocyte carcinomas (KCs) (i.e., basal cell carcinomas [BCCs] and squamous cell carcinomas [SCCs], also called nonmelanoma skin cancers [NMSCs]) are one of the most common SNs among childhood cancer survivors and show a strong association with radiation therapy.[4,82,83] Adherence to sun protection behaviors can reduce exposure to UV radiation that may exacerbate risk.
The CCSS performed a randomized, controlled, comparative effectiveness trial to test methods to improve early detection of skin cancer among survivors of childhood cancer at high risk after radiation therapy exposure. Participants were randomly assigned to the experimental arm, which included print materials in combination with mHealth strategies (text messages and use of the Advancing Survivors’ Knowledge website), or the control arm. Screening rates improved by 1.5-fold in the experimental arm. Rates of physician skin examination increased from baseline to 12 months, and rates of self-examination increased from baseline to 18 months in all three intervention groups. However, the increase in rates did not differ between the intervention groups.[84]
Sources: 84
Evidence (excess risk of KCs):
An updated analysis of the CCSS confirmed an increased risk of KCs in participants with histories of radiation therapy. Compared with participants who did not receive radiation therapy, CCSS participants treated with radiation therapy had a 4.5-fold increased risk of KCs (95% CI, 3.5–5.9).[83]
Sources: 83
An updated analysis of the CCSS confirmed an increased risk of KCs in participants with histories of radiation therapy. Compared with participants who did not receive radiation therapy, CCSS participants treated with radiation therapy had a 4.5-fold increased risk of KCs (95% CI, 3.5–5.9).[83]
The risk of KCs increased with higher radiation therapy doses. Per 10 Gy of radiation therapy at the KC site, the RR was similar for head/neck (1.0; 95% CI, 1.0–1.1) and extremity sites (1.0; 95% CI, 0.7–1.3). The RR was slightly higher for trunk sites (1.1; 95% CI, 1.0–1.3).
Allogeneic and autologous HSCT were associated with an increased risk of KCs (RR for allogeneic HSCT, 3.4; 95% CI, 2.4–4.8 and RR for autologous HSCT, 2.3; 95% CI, 1.2–4.2).
In 5,843 childhood cancer survivors in the DCOG-LATER cohort, investigators found that childhood cancer survivors had a 30-fold increased risk of developing BCCs.[30]
Sources: 30
In 5,843 childhood cancer survivors in the DCOG-LATER cohort, investigators found that childhood cancer survivors had a 30-fold increased risk of developing BCCs.[30]
After a first BCC diagnosis, 46.7% of patients developed additional BCCs.
BCC risk was associated with any radiation therapy to the relevant radiation field (site of BCC) (HR, 14.32) and with estimated percentage of exposed skin surface area (26%–75%: HR, 1.99; 76%–100%: HR, 2.16 vs. 1%–25% exposed; Ptrend among exposed = .002).
BCC risk was not associated with prescribed radiation dose and likelihood of sun-exposed skin area.
Of all chemotherapy groups examined, only vinca alkaloids increased the BCC risk (HR, 1.54).
The occurrence of a KC as the first SN has been reported to identify a population at high risk of a future invasive malignant SN.[7]
Sources: 7
The occurrence of a KC as the first SN has been reported to identify a population at high risk of a future invasive malignant SN.[7]
CCSS investigators observed a cumulative incidence of a malignant neoplasm of 20.3% (95% CI, 13.0%–27.6%) at 15 years among radiation-exposed survivors who developed a KC as a first SN, compared with 10.7% (95% CI, 7.2%–14.2%) among survivors whose first SN was an invasive malignancy.
Malignant melanoma has also been reported as an SN in childhood cancer survivor cohorts, although at a much lower incidence than NMSCs.
Risk factors for malignant melanoma identified among these studies include the following:[85]
Sources: 85
Radiation therapy (>40 Gy).
Alkylating agents.
Bleomycin.
Evidence (excess risk of melanoma):
Investigators assessed the incidence, risk factors, and outcomes for patients with melanoma in the CCSS cohort (n = 25,716).[85]
Sources: 85
Investigators assessed the incidence, risk factors, and outcomes for patients with melanoma in the CCSS cohort (n = 25,716).[85]
There were 160 survivors (median attained age, 33 years) who developed 177 melanomas (110 invasive, 62 in situ cutaneous, 5 ocular).
The 40-year cumulative incidence was 1.1% for all participants and 1.5% for those who received cumulative radiation doses of 40 Gy or higher. The standard incidence ratios were 2.0 when compared with the general population.
An increase in cutaneous melanomas was associated with a cumulative radiation dose of 40 Gy or higher to the site of the melanoma (HR, 2.0), cumulative cyclophosphamide equivalent dose of 20,000 mg/m2 or higher (HR, 1.9), and bleomycin exposure (HR, 2.2).
The presence of an invasive melanoma was associated with a twofold risk of death.
A systematic review that included data from 19 original studies (total N = 151,575 survivors; median follow-up of 13 years) observed an incidence of 10.8 cases of malignant melanoma per 100,000 childhood cancer survivors per year.[86]
Sources: 86
A systematic review that included data from 19 original studies (total N = 151,575 survivors; median follow-up of 13 years) observed an incidence of 10.8 cases of malignant melanoma per 100,000 childhood cancer survivors per year.[86]
Melanomas most frequently developed in survivors of Hodgkin lymphoma, hereditary retinoblastoma, soft tissue sarcoma, and gonadal tumors. However, the relatively small number of survivors represented in the relevant studies preclude assessment of melanoma risk among other types of childhood cancer.
Skin cancer risk after retinoblastoma
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
The incidence of melanoma and NMSC was evaluated in a cohort of 1,851 long-term, White survivors of retinoblastoma (1,020 hereditary and 831 nonhereditary) who were diagnosed from 1914 to 2006 and monitored through 2016.[87]
Sources: 87
Of all patients, 33 hereditary and 7 nonhereditary survivors developed melanoma, and 26 hereditary and 9 nonhereditary survivors developed NMSC. The median age of skin cancer development was about 20 years younger for hereditary survivors than nonhereditary survivors.
Most NMSCs were on the head/neck, whereas melanomas were more broadly distributed, with patterns similar to melanoma-prone families.
At 50 years after retinoblastoma diagnosis, in hereditary survivors, the cumulative incidence of melanoma was 4.5% and the cumulative incidence of NMSC was 3.7%. In nonhereditary survivors, the cumulative incidence of melanoma was 0.7% and the cumulative incidence of NMSC was 1.5%.
Lung cancer
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Among childhood cancer survivor cohorts, lung cancer represents a relatively uncommon SN. A PENTEC systematic review reported a median latency period of 25 years (range, 19–29 years) between the childhood cancer diagnosis and the development of a lung SN.[61] The ERR/Gy was 0.068, compared with background cumulative risks. After 20 Gy, the excess absolute risk was predicted to be 0.27% at 50 years. After 50 Gy, the excess absolute risk was predicted to be 0.7% at 50 years.[61]
Evidence (excess risk of lung cancer):
The 30-year cumulative incidence of lung cancer among CCSS participants was 0.16% (95% CI, 0.09%–0.23%), representing a SIR of 4.0 (95% CI, 2.9–5.4).[88]
Sources: 88
The 30-year cumulative incidence of lung cancer among CCSS participants was 0.16% (95% CI, 0.09%–0.23%), representing a SIR of 4.0 (95% CI, 2.9–5.4).[88]
Lung cancer risk demonstrated a dose-related association with chest radiation dose: 10 to 30 Gy (HR, 3.4; 95% CI, 1.05–11.0), more than 30 to 40 Gy (HR, 4.6; 95% CI, 1.5–14.3), and more than 40 Gy (HR, 9.1; 95% CI, 3.1–27.0).
Cumulative incidence of lung SMNs was higher among current or past smokers, compared with those who had never smoked.
The SIR for lung cancer was highest among survivors of Hodgkin lymphoma (SIR, 9.3; 95% CI, 6.2–13.4) and bone cancer (SIR, 4.4; 95% CI, 1.8–9.1).
The 25-year cumulative incidence of lung cancer among the DCOG-LATER cohort was 0.1% (95% CI, 0.0%–0.3%).[13]
Sources: 13
The 25-year cumulative incidence of lung cancer among the DCOG-LATER cohort was 0.1% (95% CI, 0.0%–0.3%).[13]
Incidence was approximately fourfold higher than what would be expected in the general population (SIR, 4.3; 95% CI, 1.9–8.5).
Lung cancer has been reported after chest irradiation for Hodgkin lymphoma.[89]
Sources: 89
Lung cancer has been reported after chest irradiation for Hodgkin lymphoma.[89]
The risk increases in association with longer elapsed time from diagnosis.
Smoking has been linked with the occurrence of lung cancer that develops after radiation therapy for Hodgkin lymphoma.[89]
Sources: 89
Smoking has been linked with the occurrence of lung cancer that develops after radiation therapy for Hodgkin lymphoma.[89]
The increase in risk of lung cancer with increasing radiation dose is greater among patients who smoke after exposure to radiation than among those who refrain from smoking (P = .04).
Gastrointestinal (GI) cancer
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
There is substantial evidence that childhood cancer survivors develop GI malignancies more frequently and at a younger age than the general population. This evidence supports the need for early initiation of colorectal carcinoma surveillance.[90-92]
Evidence (excess risk of GI cancer):
In a French and British cohort-nested, case-control study of childhood solid tumor survivors diagnosed before age 17 years, the risk of developing a digestive organ SN varied with therapy.[93]
Sources: 93
In a French and British cohort-nested, case-control study of childhood solid tumor survivors diagnosed before age 17 years, the risk of developing a digestive organ SN varied with therapy.[93]
The risk of GI cancer was 9.7-fold higher than in population controls.
The SNs most often involved the colon/rectum (42%), liver (24%), and stomach (19%).
A strong radiation dose-response relationship was observed, with an OR of 5.2 (95% CI, 1.7–16.0) for local radiation doses between 10 Gy to 29 Gy and 9.6 (95% CI, 2.6–35.2) for doses of 30 Gy and above, compared with survivors who had not received radiation therapy.
Chemotherapy alone and combined-modality therapy were associated with a significantly increased risk of developing a GI SN (SIR, 9.1; 95% CI, 2.3–23.6; SIR 29.0; 95% CI, 20.5–39.8, respectively).
The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies (PanCareSurFup) consortium quantified the absolute risks by radiation therapy treatment characteristics in a cohort of 69,450 5-year childhood cancer survivors in Europe. ORs were calculated from a case-control study comprising 143 subsequent colorectal cancers within the cohort of childhood cancer survivors.[92]
Sources: 92
The PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies (PanCareSurFup) consortium quantified the absolute risks by radiation therapy treatment characteristics in a cohort of 69,450 5-year childhood cancer survivors in Europe. ORs were calculated from a case-control study comprising 143 subsequent colorectal cancers within the cohort of childhood cancer survivors.[92]
Survivors treated with any abdominopelvic radiation therapy were three times more likely to develop a subsequent colorectal cancer than those who did not receive radiation therapy (OR, 3.1; 95% CI, 1.4–6.6).
By age 40 years, survivors who were treated with abdominopelvic radiation therapy already have a similar risk of colorectal cancer as individuals aged 50 years in the general population when population-based colorectal cancer screening begins.
The risk of colorectal cancer increases with abdominopelvic radiation therapy dose. Survivors treated with spinal or whole-abdomen radiation therapy are at higher risk than those treated with radiation to other abdominopelvic fields.
CCSS investigators reported a 4.6-fold higher risk of GI SNs among their study participants than in the general population (95% CI, 3.4–6.1).[90]
Sources: 90
CCSS investigators reported a 4.6-fold higher risk of GI SNs among their study participants than in the general population (95% CI, 3.4–6.1).[90]
The SNs most often involved the colon (39%), rectum/anus (16%), liver (18%), and stomach (13%).
The SIR for colorectal cancer was 4.2 (CI, 2.8–6.3).
The most prevalent GI SN histology was adenocarcinoma (56%).
The highest risk of GI SNs was associated with abdominal irradiation (SIR, 11.2; CI, 7.6–16.4), but survivors not exposed to radiation also had a significantly increased risk (SIR, 2.4; CI, 1.4–3.9).
High-dose procarbazine (RR, 3.2; CI, 1.1–9.4) and platinum drugs (RR, 7.6; CI, 2.3–25.5) independently increased the risk of GI SNs.
St. Jude Children's Research Hospital investigators observed that the SIR for subsequent colorectal carcinoma was 10.9 (95% CI, 6.6–17.0) compared with U.S. population controls. Investigators also observed the following:[91]
Sources: 91
St. Jude Children's Research Hospital investigators observed that the SIR for subsequent colorectal carcinoma was 10.9 (95% CI, 6.6–17.0) compared with U.S. population controls. Investigators also observed the following:[91]
Incidence of a subsequent colorectal carcinoma increased steeply with advancing attained age, with a 40-year cumulative incidence of 1.4% ± 0.53% among the entire cohort (N = 13,048) and 2.3% ± 0.83% for 5-year survivors.
Colorectal carcinoma risk increased by 70% with each 10 Gy increase in radiation dose. Increasing radiation volume also increased the risk.
Treatment with alkylating agent chemotherapy was also associated with an 8.8-fold excess risk of subsequent colorectal carcinoma.
A multi-institutional prospective study observed that potentially precancerous neoplastic polyps were found in 27.8% of childhood cancer survivors who received radiation to the abdomen/pelvis at least 10 years earlier and who had colonoscopic screening between age 35 and 49 years.[94]
Sources: 94
A multi-institutional prospective study observed that potentially precancerous neoplastic polyps were found in 27.8% of childhood cancer survivors who received radiation to the abdomen/pelvis at least 10 years earlier and who had colonoscopic screening between age 35 and 49 years.[94]
This polyp prevalence is at least as high as that previously reported for the average-risk population older than 50 years and is similar to the 24% incidence rate for patients with hereditary nonpolyposis colon cancer. Polyp prevalence rates in the general population for people aged 35 to 49 years are unclear.
A DCOG-LATER record linkage study evaluated the risk of histologically confirmed colorectal adenomas among 5,843 5-year childhood cancer survivors followed for a median of 24.9 years.[95]
Sources: 95
A DCOG-LATER record linkage study evaluated the risk of histologically confirmed colorectal adenomas among 5,843 5-year childhood cancer survivors followed for a median of 24.9 years.[95]
The cumulative incidence of colorectal adenoma by age 45 years was 3.6% among survivors who received abdominal pelvic radiation versus 2.0% for survivors who did not receive abdominal pelvic radiation, versus 1.0% among siblings.
Factors associated with adenoma risk were abdominal pelvic radiation (HR, 2.1), TBI (HR, 10.6), cisplatin (HR, 2.1 for <480 mg/m2; HR, 3.8 for ≥480 mg/m2), diagnosis of hepatoblastoma (HR, 27.1), and family history of early-onset colorectal cancer (HR, 20.5).
Procarbazine exposure was also associated with an increased risk among survivors not exposed to abdominal pelvic radiation or TBI (HR, 2.7).
The PanCareSurFup consortium reported on digestive cancers in a cohort of 69,460 5-year childhood cancer survivors in Europe.[96]
Sources: 96
The PanCareSurFup consortium reported on digestive cancers in a cohort of 69,460 5-year childhood cancer survivors in Europe.[96]
Survivors of Wilms tumor (SIR, 12.1; 95% CI, 9.6–15.1) and Hodgkin lymphoma (SIR, 7.3; 95% CI, 5.9–9.0) were at the highest risk for GI SMNs.
By age 55 years, 2.3% of survivors of Wilms tumor and Hodgkin lymphoma developed a secondary colorectal cancer, a rate that is comparable to that of the general population with two or more first-degree relatives affected by GI cancer.
A nested case-control study examined the rate of colorectal cancer according to large bowel radiation therapy dose and procarbazine dose among 5-year Hodgkin lymphoma survivors who were diagnosed between age 15 and 50 years (only 27% of cases were 15 to 24 years old) at five hospital centers in the Netherlands (diagnosed between 1964 to 2000; median follow-up, 26 years).[97]
Sources: 97
A nested case-control study examined the rate of colorectal cancer according to large bowel radiation therapy dose and procarbazine dose among 5-year Hodgkin lymphoma survivors who were diagnosed between age 15 and 50 years (only 27% of cases were 15 to 24 years old) at five hospital centers in the Netherlands (diagnosed between 1964 to 2000; median follow-up, 26 years).[97]
The median interval between Hodgkin lymphoma diagnosis and subsequent colorectal cancer was 25.7 years (range, 18.2–31.6 years).
Treatment with subdiaphragmatic radiation therapy (RR, 2.4; 95% CI, 1.4–4.1) and more than 8.4 g/m2 of procarbazine (RR, 2.5; 95% CI, 1.3–5.0) were associated with increased rates of colorectal cancer on univariable analysis.
Colorectal cancer rate increased linearly with mean radiation therapy dose to the whole large bowel and dose to the affected bowel segment. The dose response became steeper with higher doses of procarbazine and increased 1.2-fold (95% CI, 1.1–1.3) for each 1 g/m2 increase in procarbazine.
Oral cancers
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
The PanCareSurFup consortium reported on risks of oral second primary neoplasms (validated through pathology reports) in a cohort of 69,460 5-year childhood cancer survivors in Europe.[98]
Sources: 98
Oral second primary neoplasms (n = 145; 64 salivary gland, 38 tongue, 20 pharynx, 2 lip, and 21 other) developed in 143 survivors at a median age of 32 years. This represents a fivefold excess risk compared with that expected in the general population.
Childhood cancer diagnostic groups at greatest risk for an oral second primary neoplasm included leukemia (SIR, 19.2; 95% CI, 14.6–25.2), bone sarcoma (SIR, 6.4; 95% CI, 3.7–11.0), Hodgkin lymphoma (SIR, 6.2; 95% CI, 3.9–9.9), and soft tissue sarcoma (SIR, 5.0; 95% CI, 3.0–8.5).
Observed specific treatment associations with oral second primary neoplasms included radiation therapy and salivary gland neoplasms (SIR, 33; 95% CI, 25.3–44.5) and chemotherapy (any exposure) and tongue neoplasms (SIR, 15.9; 95% CI, 10.6–23.7).
Data were not available to assess the contributions of health behaviors (smoking, alcohol intake) and human papillomavirus (HPV) infection status to the development of oral second primary neoplasms.
Urogenital cancers
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Development of subsequent primary urogenital cancers in childhood and adolescent cancer survivors is rare.
Using SEER data of 43,991 patients (aged <20 years) diagnosed with a first primary cancer from 1975 to 2016, the risk of urinary system cancer was higher for both females (SIR, 5.18; 95% CI, 3.65–7.14) and males (SIR, 2.80; 95% CI, 1.94–3.92), compared with the general population.[99]
Sources: 99
Females were more likely than males to develop a subsequent urinary system cancer (SIR, 1.86; 95% CI, 1.13–3.03) and kidney cancer (SIR, 1.97; 95% CI, 1.11–3.53).
Females with any first cancer had higher risks than the general population for developing cancers of the corpus uteri (SIR, 2.32; 95% CI, 1.49–3.45) and vulva (SIR, 4.27; 95% CI, 1.38–9.95).
Renal carcinoma
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Consistent with reports among survivors of adult-onset cancer, an increased risk of renal carcinoma has been observed in survivors of childhood cancer.[29,100,101] Underlying genetic predisposition may also play a role in the risk of developing renal carcinomas because rare cases of renal carcinoma have been observed in children with tuberous sclerosis.[100] Cases of secondary renal carcinoma associated with Xp11.2 translocations and TFE3 gene fusions have also been reported and suggest that cytotoxic chemotherapy may contribute to renal carcinogenesis.[102-104]
Evidence (excess risk of renal carcinoma):
CCSS investigators reported a significant excess of subsequent renal carcinoma among 14,358 5-year survivors in the cohort (SIR, 8.0; 95% CI, 5.2–11.7) compared with the general population.[100]
Sources: 100
CCSS investigators reported a significant excess of subsequent renal carcinoma among 14,358 5-year survivors in the cohort (SIR, 8.0; 95% CI, 5.2–11.7) compared with the general population.[100]
The reported overall absolute excess risk of 8.4 per 105 person-years indicates that these cases are relatively rare. Highest risk was observed among the following:
CCSS investigators reported a significant excess of subsequent renal carcinoma among 14,358 5-year survivors in the cohort (SIR, 8.0; 95% CI, 5.2–11.7) compared with the general population.[100] › The reported overall absolute excess risk of 8.4 per 105 person-years indicates that these cases are relatively rare. Highest risk was observed among the following:
Neuroblastoma survivors (SIR, 85.8; 95% CI, 38.4–175.2).[100] Radiation has been hypothesized to predispose children with high-risk neuroblastoma to renal carcinoma.[105]
Those treated with renal-directed radiation therapy of 5 Gy or higher (RR, 3.8; 95% CI, 1.6–9.3).[100]
Sources: 100
Those treated with platinum-based chemotherapy (RR, 3.5; 95% CI, 1.0–11.2).[100]
Sources: 100
Treatment Risk Factors
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Chemotherapy (in particular, anthracyclines and anthraquinones) and radiation therapy, both independently and in combination, increase the risk of cardiovascular disease in survivors of childhood cancer and are considered to be the most important risk factors contributing to premature cardiovascular disease in this population.[3,10,17,28]
Anthracyclines and related agents
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Anthracyclines (e.g., doxorubicin, daunorubicin, idarubicin, and epirubicin) and anthraquinones (e.g., mitoxantrone) are known to directly injure cardiomyocytes through inhibition of topoisomerase 2-beta in cardiomyocytes and formation of reactive oxygen species, resulting in activation of cell-death pathways and inhibition of mitochondrial apoptosis.[29,30] The downstream results of cell death are changes in heart structure, including wall thinning, which leads to ventricular overload and pathological remodeling that, over time, leads to dysfunction and eventual clinical heart failure.[31,32]
Cumulative dose, particularly greater than 250 to 300 mg/m2.
Younger age at time of exposure, particularly children younger than 5 years.
Increased time from exposure.
While there is no definitive safe lower dose threshold, doses in excess of 250 to 300 mg/m2 have been associated with a substantially increased risk of cardiomyopathy, with cumulative incidences exceeding 5% after 20 years of follow-up, and in some subgroups, reaching or exceeding 10% cumulative incidence by age 40 years.[18,19,32]
Concurrent chest or heart radiation therapy also further increases risk of cardiomyopathy,[10,28,34] as does the presence of other cardiometabolic traits such as hypertension.[8,35]
While development of clinical heart failure can occur within a few years after anthracycline exposure, in most survivors—even those who received very high doses—clinical manifestations may not occur for decades.
Anthracycline dose equivalency
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Traditionally, anthracycline dose equivalence has largely been based on acute hematologic toxicity equivalence rather than late cardiac toxicity.
Analyses that pooled data from more than 28,000 long-term childhood cancer survivors monitored through age 40 years (resulting in 399 cardiomyopathy cases) have challenged previous assumptions that consider daunorubicin equivalent or nearly equivalent to doxorubicin.[36,37]
Analyses that pooled data from more than 28,000 long-term childhood cancer survivors monitored through age 40 years (resulting in 399 cardiomyopathy cases) have challenged previous assumptions that consider daunorubicin equivalent or nearly equivalent to doxorubicin.[36,37]
These investigations found that daunorubicin may be significantly less cardiotoxic than doxorubicin (equivalence ratio, 0.5; 95% CI, 0.4–0.7).[36]
Sources: 36
Compared with doxorubicin, mitoxantrone may be significantly more cardiotoxic than previously thought (equivalence ratio, 10.5; 95% CI, 6.2–19.1), while epirubicin appeared to be doxorubicin isoequivalent (equivalence ratio, 0.8; 95% CI, 0.3–1.4).[37]
Sources: 37
Data were too sparse to compare idarubicin with doxorubicin.
Anthracycline cardioprotection
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Cardioprotective strategies that have been explored include the following:
New, less cardiotoxic agents and liposomal formulations. In general, data on whether liposomal formulations of anthracyclines reduce cardiac toxicity in children are limited.[38,39]
Prolonged infusion time. Prolonged infusion time has been associated with reduced heart failure in adult patients, but not in children.[40,41]
Concurrent administration of cardioprotectants. A variety of agents have been tested as cardioprotectants (amifostine, acetylcysteine, calcium channel blockers, carvedilol, coenzyme Q10, and L-carnitine), but none were beneficial and are not considered standard of care.[42,43]
Dexrazoxane. There are more data for dexrazoxane as a cardioprotectant, but mainly in adult patients with cancer. In particular, the U.S. Food and Drug Administration approved dexrazoxane for women with metastatic breast cancer who have received 300 mg/m2 of anthracyclines and who may benefit from further anthracycline-based therapy.[42]
Sources: 42
Dexrazoxane. There are more data for dexrazoxane as a cardioprotectant, but mainly in adult patients with cancer. In particular, the U.S. Food and Drug Administration approved dexrazoxane for women with metastatic breast cancer who have received 300 mg/m2 of anthracyclines and who may benefit from further anthracycline-based therapy.[42]
Pediatric data show that dexrazoxane may ameliorate some markers of early cardiac toxicity for up to 5 years after therapy.[44-47]
Dexrazoxane may be associated with an increased risk of acute toxicities in some regimens.[48]
Sources: 48
A long-term study assessed outcomes of newly diagnosed children with cancer who were treated with dexrazoxane-containing regimens in randomized clinical trials (cumulative prescribed doxorubicin dose, 100–360 mg/m2; median follow-up, 18.6 years). Dexrazoxane was not associated with cancer relapse (HR, 0.84; 95% CI, 0.63–1.13), second cancers (HR, 1.19; 95% CI, 0.62–2.30), all-cause mortality (HR, 1.07; 95% CI, 0.78–1.47), or cardiovascular mortality (HR, 1.45; 95% CI, 0.41–5.16).[49]
Sources: 49
Another study evaluated long-term cardiac outcomes of 195 children with acute lymphoblastic leukemia or Hodgkin lymphoma who received doxorubicin with or without dexrazoxane in four randomized trials and patients with osteosarcoma who all received doxorubicin with dexrazoxane in a nonrandomized trial.[50]
Sources: 50
Dexrazoxane. There are more data for dexrazoxane as a cardioprotectant, but mainly in adult patients with cancer. In particular, the U.S. Food and Drug Administration approved dexrazoxane for women with metastatic breast cancer who have received 300 mg/m2 of anthracyclines and who may benefit from further anthracycline-based therapy.[42] › Another study evaluated long-term cardiac outcomes of 195 children with acute lymphoblastic leukemia or Hodgkin lymphoma who received doxorubicin with or without dexrazoxane in four randomized trials and patients with osteosarcoma who all received doxorubicin with dexrazoxane in a nonrandomized trial.[50]
At 18.1 years since cancer diagnosis (51% dexrazoxane exposed; cumulative doxorubicin dose, 297 mg/m2), dexrazoxane administration was associated with superior left ventricular fractional shortening (absolute difference, 1.4%; 95% CI, 0.3–2.5) and ejection fraction (absolute difference, 1.6%; 95% CI, 0.0–3.2) and lower myocardial stress per B-type natriuretic peptide (-6.7 pg/mL; 95% CI, -10.6 to -2.8).
Dexrazoxane use was associated with a reduced risk of lower left ventricular function (30% fractional shortening or 50% ejection fraction; OR, 0.24; 95% CI, 0.07–0.81), which was primarily observed in those treated with cumulative doxorubicin doses of 250 mg/m2 or higher.
Radiation therapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
While anthracyclines directly damage cardiomyocytes, radiation therapy primarily affects the fine vasculature of affected organs.[7]
Sources: 7
Cardiovascular disease
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Late effects of radiation therapy to the heart specifically include the following:
Delayed pericarditis, which can present abruptly or as a chronic pericardial effusion.
Pancarditis that includes pericardial and myocardial fibrosis, with or without endocardial fibroelastosis.
Cardiomyopathy (in the absence of significant pericardial disease), which can occur even without anthracycline exposure.
Ischemic heart disease.
Functional valve injury, often aortic.
Conduction defects.
These cardiac late effects are related to the following:
Individual radiation fraction size.
Total radiation dose.
Total radiation dose.
Various studies have demonstrated a substantially increased risk of these outcomes with higher radiation doses, particularly doses to the heart exceeding 35 Gy.[10,12,18,19,28]
At higher radiation doses, rates of heart failure, pericardial disease, and valvular disease have been reported to exceed 10% after 20 to 30 years. Although some studies suggest that doses less than 5 Gy may be associated with an increased risk of cardiovascular disease, the relative risk is small (i.e., 2.5) and the 95% CI is large (i.e., 0.2–41.5); moreover, the dosimetric analyses are generally estimations of incidental cardiac exposure.[10,18,28]
Low to moderate doses of radiation therapy (5.0–19.9 Gy) to large cardiac volumes (>50% of the heart) are associated with an increased rate of cardiac disease (i.e., 1.6-fold) compared with survivors who did not have any cardiac radiation therapy exposure.[19]
Sources: 19
High doses of radiation (>20 Gy) to small cardiac volumes (0.1%–29.9%) are associated with an elevated rate of cardiac disease (relative rate, 2.4).[19,52]
Additional confirmatory data are needed for an accurate assessment of risk at very low cardiac doses.
Similar to anthracyclines, manifestation of these late effects may take years, if not decades, to present.
Patients who were exposed to both radiation therapy affecting the cardiovascular system and cardiotoxic chemotherapy agents are at even greater risk of late cardiovascular outcomes.[10,19] This risk may be decreasing based on Children's Oncology Group (COG) Hodgkin lymphoma clinical trials spanning from 2002 to 2022.[53]
In a cohort study of 2,563 patients with Hodgkin lymphoma treated in four consecutive COG clinical trials between 2002 and 2022 (AHOD0031, AHOD0831, AHOD1331, S1826), the cumulative incidence of grades 3 to 5 cardiac disease was estimated to decrease, from 10% in the first trial to 6% in the last trial.
All patients received doxorubicin, 1,362 received mediastinal radiation therapy, and 307 received the cardioprotectant dexrazoxane (80% of children in the S1826 study). Radiation therapy was substantially reduced and refined, whereas the anthracycline doses were increased.
Based on modeling used as part of this study, survivors treated in the recent high-risk Hodgkin lymphoma trial (S1826), the 30-year risk of serious cardiac morbidity will be increased less than 2% above the expected rate in an untreated population (5%). Reductions in the proportion of children receiving mediastinal radiation therapy and increases in dexrazoxane use were estimated to offset the increased doxorubicin dose, producing a net reduction in late cardiac disease.
These results suggest that cardiac toxic effects are estimated to decrease from older to newer Hodgkin lymphoma trials, even in females aged 12 years and younger, who are most susceptible to anthracycline-induced heart failure.
Cerebrovascular disease
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Cerebrovascular disease after radiation therapy exposure is another potential late effect observed in survivors.
Radiation-induced vascular damage is a complex process that involves both arterial and capillary damage, with veins being less sensitive.
The spectrum of abnormalities includes lacunar lesions, vascular malformations, telangiectasias, intracranial hemorrhage, moyamoya, microbleeds, and cavernomas, each with potential symptomatic consequences.[54,55]
While brain tumor survivors have traditionally had the greatest risk, other survivors exposed to cranial irradiation (≥18 Gy) and neck irradiation (≥40 Gy), such as leukemia and lymphoma survivors, have also been reported to be at increased risk.[56-59]
In a PENTEC analysis, risk of cerebrovascular toxicity and future risk of stroke were analyzed and modeled (COX proportional hazards and baseline cumulative incidences of stroke in nonradiation therapy exposed, age-matched cancer patients and the general population).[60]
Sources: 60
In a PENTEC analysis, risk of cerebrovascular toxicity and future risk of stroke were analyzed and modeled (COX proportional hazards and baseline cumulative incidences of stroke in nonradiation therapy exposed, age-matched cancer patients and the general population).[60]
Of 3,898 pediatric patients analyzed in five reports, 101 experienced at least one cerebrovascular toxicity (e.g., transient ischemic attack [TIA], stroke, moyamoya, or arteriopathy).
The risk of any cerebrovascular toxicity was 0.2% at 30 Gy, 1.3% at 45 Gy, and 4.4% at 54 Gy (D50, 75.6 Gy; 68.4–89.4 Gy).
At an attained age of 35 years, the predicted stroke incidence at d doses was 0.9% to 1.3% at 30 Gy, 1.8% to 2.7% at 45 Gy, and 2.8% to 4.1% at 54 Gy (population baseline risk, 0.2%–0.3%).
At an attained age of 45 years, the predicted stroke incidence was 2.1% to 4.2% at 30 Gy, 4.5% to 8.6% at 45 Gy, and 6.7% to 13.0% at 54 Gy (population baseline risk, 0.5%–1.0%).
Thus, the risk of future cerebrovascular toxicity continues to rise as follow-up duration increases. Additionally, because the stroke hazard was based on prescribed tumor bed dose rather than circle-of-Willis dose, the reported stroke risk was likely underestimated.
In lymphoma survivors who received only chest and/or neck radiation therapy, cerebrovascular disease is thought to be caused by large-vessel atherosclerosis and cardiac embolism.[57]
Sources: 57
The risk increases with cumulative dose received. One study (N = 325) reported that the stroke hazard increased by 5% (HR, 1.05; 95% CI, 1.01–1.09; P = .02), with each 1 Gy increase in the radiation dose, leading to a cumulative incidence of 2% for the first stroke after 5 years and 4% after 10 years.[61]
Sources: 61
Survivors who experienced a stroke were at much greater risk of recurrent strokes.[62]
Sources: 62
Evidence (selected studies describing prevalence of and risk factors for cerebrovascular accident [CVA]/vascular disease):
The population-based British Childhood Cancer Survivor Study (n = 13,457) used Hospital Episode Statistics data for England to assess the risk of cerebrovascular-related hospitalizations (e.g., nontraumatic intracranial hemorrhage, cerebral infarction, or cerebral artery occlusion), particularly in patients older than 50 years.[59]
Sources: 59
The population-based British Childhood Cancer Survivor Study (n = 13,457) used Hospital Episode Statistics data for England to assess the risk of cerebrovascular-related hospitalizations (e.g., nontraumatic intracranial hemorrhage, cerebral infarction, or cerebral artery occlusion), particularly in patients older than 50 years.[59]
They found that 2.3% of the survivors had been hospitalized at least once for cerebrovascular disease, with a fourfold risk compared with the expected rate.
Survivors of central nervous system (CNS) tumors or leukemia who received cranial irradiation were at greatest risk of cerebrovascular disease (CNS tumor standardized hospitalization ratio [SHR], 15.6; 95% CI, 14.0–17.4 and leukemia SHR, 5.4; 95% CI, 4.5–6.4).
Beyond age 60 years, on average, 3.1% of CNS tumor survivors treated with cranial irradiation were hospitalized annually for cerebrovascular disease. By age 65 years, as many as 26% of these patients will have been hospitalized for a cerebrovascular event.
CCSS investigators observed that 295 of 13,060 participants (35% treated with cranial radiation therapy) reported having a stroke (6.3%; 95% CI, 5.1%–7.5%) by age 50 years (median follow-up, 19 years). For survivors considered to be high risk, the cumulative incidence of cerebrovascular disease up to age 50 was 19.9%.[63]
Sources: 63
A retrospective study of 3,172 5-year survivors of childhood cancer monitored for a mean time of 26 years was formed from the Euro2K cohort, which included eight centers in France and the United Kingdom. Radiation doses to the circle of Willis were estimated for each of the 2,202 children who received radiation therapy.[64]
Sources: 64
A retrospective study of 3,172 5-year survivors of childhood cancer monitored for a mean time of 26 years was formed from the Euro2K cohort, which included eight centers in France and the United Kingdom. Radiation doses to the circle of Willis were estimated for each of the 2,202 children who received radiation therapy.[64]
Patients who received radiation therapy had an 8.5-fold increased risk (95% CI, 6.3–11.0) of stroke in contrast to a nonelevated risk for patients who did not receive radiation therapy.
The relative risk was 15.7 (95% CI, 4.9–50.2) for doses of 40 Gy or higher.
At age 45 years, the cumulative incidence was 11.3% (95% CI, 7.1%–17.7%) in patients who received 10 Gy or higher to the circle of Willis, compared with 1% in the general population.
Investigators from the Teenage and Young Adult Cancer Survivor Study (N = 178,962) evaluated the risk of hospitalization for a cerebrovascular event among 5-year survivors of cancer diagnosed between age 15 and 39 years.[65]
Sources: 65
Investigators from the Teenage and Young Adult Cancer Survivor Study (N = 178,962) evaluated the risk of hospitalization for a cerebrovascular event among 5-year survivors of cancer diagnosed between age 15 and 39 years.[65]
The investigators found that survivors of adolescent and young adult cancers had a 40% increased risk of hospitalization for cerebrovascular event compared with the general population.
Survivors of CNS tumors (SHR, 4.6), head and neck tumors (SHR, 2.6), and leukemia (SHR, 2.5) had the highest risk of hospitalization for a cerebrovascular complication.
Males had significantly higher absolute excess risks than did females, especially among head and neck tumor survivors. By age 60 years, 9% of CNS tumor survivors, 6% of head and neck tumor survivors, and 5% of leukemia survivors had been hospitalized for a cerebrovascular event.
The risk of hospitalization for a cerebral infarction was particularly increased among survivors of a CNS tumor older than 60 years, whereas this risk was increased across all ages in survivors of head and neck tumors.
CCSS investigators evaluated the rates and predictors of recurrent stroke among participants who reported a first stroke.[62]
Sources: 62
CCSS investigators evaluated the rates and predictors of recurrent stroke among participants who reported a first stroke.[62]
Among responding participants (329 of 443), 271 confirmed a first stroke (at median age, 19 years) and 70 reported a second stroke (at median age, 32 years).
Independent predictors of recurrent stroke included treatment with a cranial radiation therapy dose of 50 Gy or higher (vs. no cranial radiation therapy), history of hypertension, and age 40 years or older at first stroke (vs. age 0–17 years).
The 10-year cumulative incidence of late recurrent stroke was 21% overall and 33% for those treated with 50 Gy or higher of cranial radiation therapy.
A follow-up study of 224 CCSS participants who experienced stroke demonstrated an increased risk of all-cause and health-related mortality and a negative impact on social attainment, neurocognitive function, emotional distress, and other health-related quality-of-life measures.[66]
Sources: 66
A multicenter retrospective Dutch study evaluated 5-year survivors of Hodgkin lymphoma diagnosed before age 51 years (25% pediatric-aged patients) who were followed for a median of 18 years. Among 2,201 survivors, 96 developed cerebrovascular disease (CVA and TIA).[57]
Sources: 57
A multicenter retrospective Dutch study evaluated 5-year survivors of Hodgkin lymphoma diagnosed before age 51 years (25% pediatric-aged patients) who were followed for a median of 18 years. Among 2,201 survivors, 96 developed cerebrovascular disease (CVA and TIA).[57]
Most ischemic events were from large-artery atherosclerosis (36%) or cardiac embolism (24%).
The cumulative incidence of ischemic CVA or TIA 30 years after lymphoma treatment was 7%.
The overall standardized incidence ratio (SIR) was 2.2 for CVA and 3.1 for TIA. However, SIR estimates appeared to be greater among childhood cancer survivors, with SIRs of 3.8 for CVA and 7.6 for TIA.
Irradiation to the neck and mediastinum was an independent risk factor for ischemic cerebrovascular disease (HR, 2.5; 95% CI, 1.1–5.6) versus no radiation therapy. Treatment with chemotherapy was not associated with increased risk.
Hypertension, diabetes mellitus, and hypercholesterolemia were associated with the occurrence of ischemic cerebrovascular disease.
Venous thromboembolism
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Children with cancer have an excess risk of venous thromboembolism within the first 5 years after diagnosis. However, the long-term risk of venous thromboembolism among childhood cancer survivors has not been well studied.[67]
Sources: 67
CCSS investigators evaluated self-reported late-onset (5 or more years after cancer diagnosis) venous thromboembolism among cohort members (median follow-up, 21.3 years).[68]
Sources: 68
The 35-year cumulative incidence of venous thromboembolism among survivors was 4.9%. This risk was twofold higher when compared with a sibling cohort (rate ratio, 2.2; 95% CI, 1.7–2.8).
Risk factors for venous thromboembolism among survivors included female sex, treatment with cisplatin or asparaginase, being affected by obesity or underweight, and recurrent primary or subsequent cancer.
The risk of late venous thromboembolism was higher among survivors of lower-extremity osteosarcoma treated with limb-sparing surgery compared with patients treated with amputation, possibly resulting from alterations in peripheral vascular anatomy and homeostasis.
Venous thromboembolism was associated with an almost-twofold increased risk of late mortality (RR, 1.9; 95% CI, 1.6–2.3).
Conventional cardiovascular conditions
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Various cancer treatment exposures may also directly or indirectly influence the development of hypertension, diabetes mellitus, and dyslipidemia.
These conditions remain important among cancer survivors, as they do in the general population, in that they are independent risk factors in the development of cardiomyopathy, ischemic heart disease, and cerebrovascular disease.[8,69-72]
Childhood cancer survivors should be closely monitored for the development of these cardiovascular conditions because they represent potentially modifiable targets for intervention.
Related conditions such as obesity and various endocrinopathies (e.g., hypothyroidism, hypogonadism, growth hormone deficiency) that may be more common among subsets of childhood cancer survivors also need to be monitored. If these conditions are untreated/uncontrolled, they may be associated with a metabolic profile that increases cardiovascular risk.[9] For more information, see the Risk prediction for cardiovascular diseases section.
Sources: 9 · Risk prediction for cardiovascular diseases
Cognitive outcomes after proton radiation therapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Data are emerging regarding cognitive outcomes after proton radiation to the CNS.[50-52] However, these studies have been limited by retrospective analysis of cognitive outcomes among relatively small clinically heterogenous pediatric brain tumor cohorts and the use of historically treated photon patients or population standards as comparison groups.
In studies largely describing IQ changes during early follow-up (<5 years from radiation), results demonstrate lack of difference in slopes of IQ change among photon-treated and proton-treated patients [50] and significant declines in cognitive processing speed among patients treated with proton radiation.[51]
One study compared the intellectual trajectories between pediatric patients with medulloblastoma who were treated with proton and photon radiation therapy (4.3-year mean follow-up after median 23.4-Gy craniospinal irradiation dose). Notably, boost dose and margins were significantly different between the two groups.[52]
Sources: 52
One study compared the intellectual trajectories between pediatric patients with medulloblastoma who were treated with proton and photon radiation therapy (4.3-year mean follow-up after median 23.4-Gy craniospinal irradiation dose). Notably, boost dose and margins were significantly different between the two groups.[52]
Children treated with proton radiation therapy exhibited superior long-term outcomes in global IQ, perceptual reasoning, and working memory compared with children who were treated with photon radiation therapy.
The photon radiation therapy group exhibited a significant decline in global IQ, working memory, and processing speed.
The proton radiation therapy group exhibited stable scores over time in all domains, except for processing speed.
Considering the relatively brief follow-up time from radiation, longitudinal follow-up is important to determine whether proton radiation provides a clinically meaningful benefit in sparing cognitive function compared with photon radiation. In addition, more targeted radiation treatment volumes with photons may diminish potential differences.
ALL and chemotherapy-only CNS therapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Because of its penetrance into the CNS, systemic methotrexate has been used in a variety of low-dose and high-dose regimens for leukemia CNS prophylaxis.
Systemic methotrexate in high doses with or without radiation therapy can lead to an infrequent but well-described leukoencephalopathy, which has been linked to neurocognitive impairment.[53]
Sources: 53
When neurocognitive outcomes after radiation therapy and chemotherapy-only regimens are directly compared, the evidence suggests a better outcome for those treated with chemotherapy alone, although some studies show no significant difference.[60,61]
In a longitudinal analysis of 210 childhood ALL survivors, the development of acute leukoencephalopathy during chemotherapy-only CNS therapy predicted higher risks of developing long-term neurobehavioral problems (e.g., deficits in organization and task initiation [components of executive function]) and reduced white matter integrity in frontal brain regions.[62]
Sources: 62
Compared with cranial irradiation, chemotherapy-only CNS-directed treatment produces neurocognitive deficits involving processes of attention, speed of information processing, memory, verbal comprehension, visual-spatial skills, visual-motor functioning, and executive functioning. Global intellectual function is typically preserved.[56,60,63-65]
Few longitudinal studies evaluating long-term neurocognitive outcome report adequate data for a decline in global IQ after treatment with chemotherapy alone.[63]
Sources: 63
The academic achievement of ALL survivors in the long term seems to be generally average for reading and spelling, with deficits mainly affecting arithmetic performance.[60,66]
Risk factors for poor neurocognitive outcome after chemotherapy-only CNS-directed treatment are younger age and female sex.[65,67]
Reduced cognitive status has been observed in association with reduced integrity in neuroanatomical regions essential in memory formation (e.g., reduced hippocampal volume with increased activation and thinner parietal cortices).[62]
Sources: 62
The long-term impact of these prevalent neurocognitive and neuroimaging abnormalities on functional status in aging adults treated for childhood ALL, particularly those treated with contemporary approaches using chemotherapy alone, remains an active area of research.
Research in childhood ALL survivors treated with chemotherapy alone suggests that genetic predisposition may modulate risk of developing neurocognitive late effects. It also provides insights into potential mechanisms underlying neurocognitive deficits.[68,69]
Evidence (neurocognitive functioning in large pediatric cancer survivor cohorts):
CCSS investigators identified sex-specific associations between treatment and chronic health conditions with neurocognitive impairment among 1,207 survivors of ALL (mean age, 30.6 years) who were treated with chemotherapy only.[7]
Sources: 7
CCSS investigators identified sex-specific associations between treatment and chronic health conditions with neurocognitive impairment among 1,207 survivors of ALL (mean age, 30.6 years) who were treated with chemotherapy only.[7]
Both male and female survivors reported increased prevalence of impaired task efficiency (attention and processing speed; adjusted odds ratio [OR], 1.89 for males; OR, 1.50 for females) and impaired memory (OR, 1.89 for males; OR, 1.96 for females) compared with 2,273 same-sex siblings.
Among male survivors, impaired task efficiency was associated with grades 2 to 4 neurological conditions (OR, 4.33) and pulmonary conditions (OR, 4.99). Impaired memory was associated with increased cumulative dose of intrathecal methotrexate (OR, 1.68) and exposure to dexamethasone (OR, 2.44).
In female survivors, grades 2 to 4 endocrine conditions were associated with higher risk of impaired task efficiency (OR, 2.19) and memory (OR, 2.26).
The CCSS examined parent-reported cognitive, behavior, and learning problems from 1,560 adolescent survivors of childhood ALL who were treated with chemotherapy alone between 1970 and 1999.[70]
Sources: 70
The CCSS examined parent-reported cognitive, behavior, and learning problems from 1,560 adolescent survivors of childhood ALL who were treated with chemotherapy alone between 1970 and 1999.[70]
Survivors treated with cranial irradiation had significantly higher frequency of problems in anxiety-depression, inattention-hyperactivity, and social withdrawal than did patients who were not treated with cranial irradiation.
Compared with siblings, survivors treated with chemotherapy only were more likely to demonstrate headstrong behavior (19% of survivors vs. 14% of siblings, P = .010), inattention-hyperactivity (19% vs. 14%, P < .0001), social withdrawal (18% vs. 12%, P = .002), and had higher rates of learning problems (28% vs. 14%, P < .0001).
In multivariable models among survivors, increased cumulative dose of intravenous methotrexate (i.e., >4.3 g/m2) conferred increased risk of inattention-hyperactivity (RR, 1.53).
Adolescent survivors with cognitive or behavior problems and those with learning problems were less likely to graduate from college as young adults than adolescent survivors without cognitive or behavior problems.
Inattention and hyperactivity problems were associated with the highest risk of special education placement during adolescence. Participation in special education during adolescence did not improve adult educational attainment.
The SJCRH TOTAL XVI (NCT00549848) trial evaluated whether a higher dose of pegaspargase and early intensification of triple intrathecal therapy (ITT; methotrexate, hydrocortisone, and cytarabine) would improve systemic and CNS control in children with newly diagnosed ALL. Intensified ITT was defined as more than 21 cumulative doses for patients with low-risk ALL (70 of 194) and more than 27 doses for those with standard- and high-risk ALL (81 of 206). Neurocognitive testing was completed at the end of therapy.[71]
Sources: TOTAL XVI (NCT00549848) · 71
The SJCRH TOTAL XVI (NCT00549848) trial evaluated whether a higher dose of pegaspargase and early intensification of triple intrathecal therapy (ITT; methotrexate, hydrocortisone, and cytarabine) would improve systemic and CNS control in children with newly diagnosed ALL. Intensified ITT was defined as more than 21 cumulative doses for patients with low-risk ALL (70 of 194) and more than 27 doses for those with standard- and high-risk ALL (81 of 206). Neurocognitive testing was completed at the end of therapy.[71]
The overall group had below age-based norms on measures of global intelligence (P < .0001), attention (P = .0051), working memory (P = .0001), processing speed (P = .0002), fine motor speed (P = .0001), and math skills (P = .0087). Caregiver ratings of patient functioning showed elevated risks of problems in attention (P = .0173), executive function (P = .0001), and adaptive skills (P = .0001).
In the low-risk group, there were no significant differences between patients treated with and without intensified ITT.
Patients with standard- and high-risk ALL who were treated with intensified ITT had poorer working memory (P = .0328) and fine motor speed (P = .0403), and elevated ratings of inattention (P = .0189) and executive dysfunction (P = .0245). Females in this risk group treated with intensified ITT had lower working memory scores.
In the SJCRH Total XV (NCT00137111) trial, which omitted prophylactic cranial irradiation, comprehensive cognitive testing of 243 participants at week 120 revealed the following:[72]
Sources: Total XV (NCT00137111) · 72
In the SJCRH Total XV (NCT00137111) trial, which omitted prophylactic cranial irradiation, comprehensive cognitive testing of 243 participants at week 120 revealed the following:[72]
A higher risk of below-average performance on a measure of sustained attention but not on measures of intellectual functioning, academic skills, or memory.
The risk of cognitive deficits correlated with treatment intensity but not with age at diagnosis or sex.
Prolonged follow-up (average, 7.7 years from diagnosis) of this cohort demonstrated that intelligence was within normal limits compared with population expectations, but measures of executive function, processing speed, and memory were less than population means.
Higher plasma methotrexate was associated with executive dysfunction, thicker cerebral cortex, and higher activity in frontal brain regions on functional MRI.
In a large prospective study of neurocognitive outcomes in children with newly diagnosed ALL, 555 children were randomly assigned to receive CNS-directed therapy according to risk group.[73]
Sources: 73
In a large prospective study of neurocognitive outcomes in children with newly diagnosed ALL, 555 children were randomly assigned to receive CNS-directed therapy according to risk group.[73]
The low-risk group was randomly assigned to receive either intrathecal methotrexate or high-dose methotrexate.
The high-risk group was randomly assigned to receive either high-dose methotrexate or 24 Gy of cranial radiation therapy.
A significant reduction in IQ scores (4–7 points) was observed in all patient groups when compared with controls, regardless of the CNS treatment delivered.
Children younger than 5 years at diagnosis were more likely to have IQs below 80 at 3 years posttherapy than were children older than 5 years at diagnosis, irrespective of treatment allocation, suggesting that younger children are more vulnerable to treatment-related neurological toxic effects.
Persistent cognitive deficits and progressive intellectual decline have been observed in cohorts of adults treated for ALL during childhood and associated with reduced educational attainment and unemployment.[5,55,59] The results of a study of more than 500 adult survivors of childhood ALL (average, 26 years postdiagnosis) showed the following:[55]
Persistent cognitive deficits and progressive intellectual decline have been observed in cohorts of adults treated for ALL during childhood and associated with reduced educational attainment and unemployment.[5,55,59] The results of a study of more than 500 adult survivors of childhood ALL (average, 26 years postdiagnosis) showed the following:[55]
Survivors demonstrated increased rates of impairment across all neurocognitive domains (ranging from 28.6%–58.9% for each domain).
Rate of severe impairment increased as a function of cranial radiation dose and was common among survivors treated with lower doses of cranial irradiation and chemotherapy only.
Impairment in executive function skills increased with time since diagnosis in a cranial radiation dose-dependent manner; impairment in intellect, academics, and memory progressively increased with younger age at treatment in a cranial radiation dose-dependent manner; and neurocognitive impairment was related to functional outcomes as adults, including reduced likelihood of college graduation and full-time employment.
ALL and steroid therapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
The type of steroid used for ALL systemic treatment may affect cognitive functioning.
In a study that involved long-term neurocognitive testing (mean follow-up, 9.8 years) of 92 children with a history of standard-risk ALL who had received either dexamethasone or prednisone during treatment, no meaningful differences in mean neurocognitive and academic performance scores were observed.[74]
Sources: 74
In contrast, in a study of 567 adult survivors of childhood leukemia (mean age, 33 years; mean time since diagnosis, 26 years), the following was reported:[55]
Sources: 55
In contrast, in a study of 567 adult survivors of childhood leukemia (mean age, 33 years; mean time since diagnosis, 26 years), the following was reported:[55]
Dexamethasone exposure was associated with increased risk of impairment in attention (RR, 2.12; 95% confidence interval [CI], 1.11–4.03) and executive function (RR, 2.42; 95% CI, 1.20–4.91), independent of methotrexate exposure.
Intrathecal hydrocortisone also increased risk of attention problems (RR, 1.24; 95% CI, 1.05–1.46).
Radiation therapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Radiation directed at the oral cavity or surrounding structures increases the risk of dental anomalies because ameloblasts can be permanently damaged by doses as low as 10 Gy. In addition, salivary function is impacted by exposure to major and minor glands.[3-5]
The most significant degree of tooth aplasia or delayed eruption occurs in younger children (aged <4 years) who are exposed to radiation doses of 20 Gy or higher.[13]
Sources: 13
Developing teeth may be irradiated when treating head and neck sarcomas, Hodgkin lymphoma, neuroblastoma, central nervous system leukemia, nasopharyngeal cancer, and brain tumors, or during total-body irradiation (TBI) for HSCT.
Doses of 10 Gy to 40 Gy can cause root shortening or abnormal curvature, dwarfism, and hypocalcification.[14]
Sources: 14
Significant dental abnormalities, including mandibular or maxillary hypoplasia, increased caries, hypodontia, microdontia, root stunting, and xerostomia have been reported in more than 85% of survivors of head and neck rhabdomyosarcoma treated with radiation doses higher than 40 Gy.[4,15]
In the St. Jude Life (SJLIFE) cohort, survivors who received radiation therapy that potentially exposed the oral cavity were more likely to report at least one dental health problem (odds ratio [OR], 1.48; 95% confidence interval [CI], 1.26–1.72) and at least one soft tissue abnormality (OR, 1.52; 95% CI, 1.25–1.84) after controlling for socioeconomic factors, age at last follow-up and diagnosis, other treatment exposures, and access to dental services.[12]
Sources: 12
Chemotherapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Chemotherapy, especially exposure to alkylating agents, can affect tooth development.[3,5,6]
Chemotherapy for the treatment of leukemia or neuroblastoma is associated with shortening and thinning of the premolar roots and enamel abnormalities.[8,16,17]
Childhood Cancer Survivor Study (CCSS) investigators identified age younger than 5 years and increased exposure to cyclophosphamide as significant risk factors for developmental dental abnormalities in long-term survivors of childhood cancer.[3]
Sources: 3
In the SJLIFE study, survivors who received classic alkylating agents (OR, 1.6; 95% CI, 1.36–1.88) or anthracycline antibiotics (OR, 1.22; 95% CI, 1.04–1.42) were more likely to report at least one dental health problem after controlling for socioeconomic factors, age at last follow-up and diagnosis, other treatment exposures, and access to dental services.[12]
Sources: 12
Radiation therapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Salivary gland irradiation incidental to treatment of head and neck malignancies or Hodgkin lymphoma causes a qualitative and quantitative change in salivary flow, which can be reversible after doses of lower than 40 Gy but may be irreversible after higher doses, depending on whether sensitizing chemotherapy is also administered.[18]
Sources: 18
In a German study of 114 pediatric patients, the risk of acute and late xerostomia increased with parotid and submandibular gland dose. In general, grade 1 or higher xerostomia was seen in patients who received a maximum dose of higher than 20 Gy to the salivary glands. The odds of both acute and late xerostomia were higher in patients who received concurrent chemotherapy compared with those who received radiation therapy alone, with an OR for acute xerostomia of 3.64 (95% CI, 1.49–8.89) and for late xerostomia of 5.15 (95% CI, 1.20–22.15).[21]
Sources: 21
The Pediatric Normal Tissue Effects in the Clinic (PENTEC) initiative reported on late effects for childhood cancer survivors who were treated with radiation therapy for head and neck cancers.[22] Grades 1 or higher xerostomia were seen in patients who received a maximum dose of more than 20 Gy to the salivary glands. The odds of both acute and chronic xerostomia were greater in patients who had received concurrent chemotherapy and radiation therapy (acute xerostomia OR, 3.64; 95% CI, 1.49–8.89 and late xerostomia OR, 5.15; 95% CI, 1.20–22.15), compared with patients who were treated with radiation therapy alone. A mean parotid dose of 35 to 40 Gy was associated with a 32% risk of higher than grade 2 acute xerostomia and a 13% to 32% risk of chronic xerostomia.
Sources: 22
Chemotherapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
The association of chemotherapy alone with xerostomia remains controversial.[18]
Sources: 18
Only one study of pediatric patients demonstrated an excess risk (OR, 12.32; 95% CI, 2.1–74.4) of decreased stimulated saliva flow rates among patients treated with cyclophosphamide. However, an increase in dental caries was not noted and patient-reported xerostomia was not evaluated.[6]
Sources: 6
Posttherapy management
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Some studies suggest that fluoride products or chlorhexidine rinses may be beneficial in patients who have undergone radiation therapy.[28]
Sources: 28
Dental caries are a problematic consequence of reduced salivary quality and flow. The use of topical fluoride can dramatically reduce the frequency of caries, and saliva substitutes and sialagogues can ameliorate sequelae such as xerostomia.[19]
Sources: 19
For more information about oral complications in cancer patients, see Oral Complications of Cancer Therapies.
Table 5 summarizes oral and dental late effects and the related health screenings.
Sources: Table 5
| Predisposing Therapy | Oral/Dental Effects | Health Screening/Interventions |
|---|---|---|
| CT = computed tomography; GVHD = graft-versus-host disease; HSCT = hematopoietic stem cell transplant; MRI = magnetic resonance imaging. | ||
| aAdapted from the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. | ||
| Any chemotherapy; radiation exposing oral cavity | Dental developmental abnormalities; tooth/root agenesis; microdontia; root thinning/shortening; enamel dysplasia | Dental evaluation and cleaning every 6 months |
| Regular dental care including fluoride applications | ||
| Consultation with orthodontist experienced in management of irradiated childhood cancer survivors | ||
| Baseline Panorex x-ray before dental procedures to evaluate root development | ||
| Radiation exposing oral cavity | Malocclusion; temporomandibular joint dysfunction | Dental evaluation and cleaning every 6 months |
| Regular dental care including fluoride applications | ||
| Consultation with orthodontist experienced in management of irradiated childhood cancer survivors | ||
| Baseline Panorex x-ray before dental procedures to evaluate root development | ||
| Referral to otolaryngologist for assistive devices for jaw opening | ||
| Radiation exposing oral cavity; HSCT with history of chronic GVHD | Xerostomia/salivary gland dysfunction; periodontal disease; dental caries; oral cancer (squamous cell carcinoma) | Dental evaluation and cleaning every 6 months |
| Supportive care with saliva substitutes, moistening agents, and sialogogues (pilocarpine) | ||
| Regular dental care including fluoride applications | ||
| Referral for biopsy of suspicious lesions | ||
| Radiation exposing oral cavity (≥40 Gy) | Osteoradionecrosis | History: impaired or delayed healing after dental work |
| Examination: persistent jaw pain, swelling or trismus | ||
| Imaging studies (x-ray, CT scan and/or MRI) may assist in making diagnosis | ||
| Surgical biopsy may be needed to confirm diagnosis | ||
| Consider hyperbaric oxygen treatments | ||
Treatment-related risk factors for hepatobiliary late effects
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
The type and intensity of previous therapy influences risk for late-occurring hepatobiliary effects. In addition to the risk of treatment-related toxicity, recipients of HSCT frequently experience chronic liver dysfunction related to microvascular, immunologic, infectious, metabolic, and other toxic etiologies.
Key findings related to cancer treatment effect on hepatobiliary complications include the following:
Chemotherapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Chemotherapeutic agents with established hepatotoxic potential include antimetabolite agents like 6-mercaptopurine, 6-thioguanine, methotrexate, and rarely, dactinomycin.
Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) and cholestatic disease have been observed after thiopurine administration, especially 6-thioguanine.[60]
Sources: 60
Progressive fibrosis and portal hypertension have been reported in a subset of children who developed VOD/SOS after treatment with 6-thioguanine.[60]
Sources: 60
Acute, dose-related, reversible VOD/SOS has been observed in children treated with dactinomycin for pediatric solid tumors.[61,62]
In the transplant setting, VOD/SOS has also been observed after conditioning regimens that have included cyclophosphamide/TBI, busulfan/cyclophosphamide, and carmustine/cyclophosphamide/etoposide.[63] High-dose cyclophosphamide, common to all of these regimens, is speculated to be a potential causative factor.
Sources: 63
Radiation therapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Acute radiation-induced liver disease also causes endothelial cell injury that is characteristic of VOD/SOS.[64]
Sources: 64
In adults, the whole liver has tolerance up to 30 Gy to 35 Gy with conventional fractionation, the prevalence of radiation-induced liver disease varies from 6% to 66% based on the volume of liver involved and on hepatic reserve.[64,65]
Radiation hepatopathy after contemporary treatment appears to be uncommon in long-term survivors without predisposing conditions, such as viral hepatitis or iron overload.[66]
Sources: 66
The risk of injury in children increases with radiation dose, hepatic volume, younger age at treatment, previous partial hepatectomy, and concomitant use of radiomimetic chemotherapy, such as dactinomycin and doxorubicin.[67-70]
Survivors who received radiation doses of 40 Gy to at least one-third of the liver volume, doses of 30 Gy or higher to the whole abdomen, or an upper abdominal field involving the entire liver are at highest risk for hepatic dysfunction.[42]
Sources: 42
A PENTEC comprehensive review was performed to develop models to inform dose constraints for radiation-associated hepatic toxicity.[71]
Sources: 71
A PENTEC comprehensive review was performed to develop models to inform dose constraints for radiation-associated hepatic toxicity.[71]
In a model developed to calculate the risk of developing SOS after whole-liver radiation therapy, radiation dose and receipt of nonalkylating chemotherapy were significant. Age younger than 20 years at the time of radiation therapy was borderline significant.
The predicted risk of SOS was 2% with zero radiation therapy dose, 6.1% after treatment with 10 Gy, and 14.5% after treatment with 20 Gy to the whole liver.
Patients with Wilms tumor treated with right flank radiation therapy (estimated dose, 6.54 ± 2.50 Gy) had a higher observed rate of SOS than patients who received left flank radiation therapy (estimated dose, 2.16 ± 1.15 Gy).
Data were sparse regarding rates of late liver injury after radiation therapy, which suggests low rates of severe toxicity after treatment for common pediatric malignancies.
HSCT
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Chronic liver dysfunction in patients after HSCT is multifactorial in etiology with the most common etiologies including iron overload, chronic GVHD, and viral hepatitis.[72]
Sources: 72
Patients with chronic GVHD of the GI tract who exhibit an elevated bilirubin have a worse prognosis and quality of life.[73]
Sources: 73
While chronic liver dysfunction may be seen in more than one-half of long-term HSCT survivors, and the course of the disease appears to be indolent, continued follow-up is needed to establish its long-term impact on survivor health.[74]
Sources: 74
Posttherapy management
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Survivors with liver dysfunction should be counseled regarding risk-reduction methods to prevent hepatic injury.
Standard recommendations include maintenance of a healthy body weight, abstinence from alcohol use, and immunization against hepatitis A and B viruses.[42]
Sources: 42
In patients with chronic hepatitis, precautions to reduce viral transmission to household and sexual contacts should also be reviewed.
Table 7 summarizes hepatobiliary late effects and the related health screenings.
Sources: Table 7
| Predisposing Therapy | Hepatic Effects | Health Screening/Interventions |
|---|---|---|
| ALT = alanine aminotransferase; AST = aspartate aminotransferase; HSCT = hematopoietic stem cell transplant. | ||
| aAdapted from the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. | ||
| Methotrexate; mercaptopurine/thioguanine; HSCT | Hepatic dysfunction | Laboratory tests: ALT, AST, bilirubin levels |
| Ferritin in those treated with HSCT | ||
| Mercaptopurine/thioguanine; HSCT | Veno-occlusive disease/sinusoidal obstructive syndrome | Examination: scleral icterus, jaundice, ascites, hepatomegaly, splenomegaly |
| Laboratory tests: ALT, AST, bilirubin, platelet levels | ||
| Ferritin in those treated with HSCT | ||
| Radiation exposing liver/biliary tract; HSCT | Hepatic fibrosis/cirrhosis; focal nodular hyperplasia | Examination: jaundice, spider angiomas, palmar erythema, xanthomata, hepatomegaly, splenomegaly |
| Laboratory tests: ALT, AST, bilirubin levels | ||
| Ferritin in those treated with HSCT | ||
| Prothrombin time for evaluation of hepatic synthetic function in patients with abnormal liver screening tests | ||
| Screen for viral hepatitis in patients with persistently abnormal liver function or any patient transfused before 1993 | ||
| Gastroenterology/hepatology consultation in patients with persistent liver dysfunction | ||
| Hepatitis A and B immunizations in patients lacking immunity | ||
| Consider phlebotomy and chelation therapy for iron overload | ||
| Radiation exposing liver/biliary tract | Cholelithiasis | History: colicky abdominal pain related to fatty food intake, excessive flatulence |
| Examination: right upper quadrant or epigastric tenderness (acute episode) | ||
| Consider gallbladder ultrasonography in patients with chronic abdominal pain | ||
Growth hormone replacement therapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Growth hormone replacement therapy provides the benefit of optimizing height outcomes among children who have not reached skeletal maturity.[43] The diagnosis requires specialized dynamic testing.[43,72]
Treatment with recombinant growth hormone (rGH) replacement therapy is generally delayed until 12 months after successful completion of cancer or brain tumor treatments and after a multidisciplinary discussion involving the prescribing pediatric endocrinologist, the primary oncologist, and other providers selected by the patient or family.[73]
Sources: 73
Safety concerns pertaining to the use of rGH in childhood cancer survivors have primarily been related to the mitogenic potential of the growth hormone stimulating tumor growth in a population with an increased risk of second neoplasms.[74] Most studies that report these outcomes, however, are limited by selection bias and small sample size.
Sources: 74
Evidence (subsequent neoplasm risk after growth hormone deficiency replacement therapy):
One study evaluated 361 growth hormone–treated cancer survivors enrolled in the CCSS and compared risk of recurrence, risk of subsequent neoplasm, and risk of death among survivors who did and did not receive treatment with growth hormone.[75]
Sources: 75
One study evaluated 361 growth hormone–treated cancer survivors enrolled in the CCSS and compared risk of recurrence, risk of subsequent neoplasm, and risk of death among survivors who did and did not receive treatment with growth hormone.[75]
The RR of disease recurrence was 0.83 (95% CI, 0.37–1.86) for growth hormone–treated survivors.
Growth hormone–treated participants were diagnosed with 15 subsequent neoplasms, all solid tumors, for an overall RR of 3.21 (95% CI, 1.88–5.46). This was mainly due to a small excess number of subsequent neoplasms observed in survivors of acute leukemia.[75]
Sources: 75
With prolonged follow-up, the elevation of subsequent cancer risk resulting from growth hormone diminished.[76]
Sources: 76
Compared with survivors not treated with growth hormone, those who were treated had a twofold excess risk of developing a subsequent neoplasm (RR, 2.15; 95% CI, 1.33–3.47; P < .002). Meningiomas were the most commonly observed neoplasms (9 of 20 tumors).[75]
Sources: 75
A study from the CCSS reported on the risk of subsequent CNS neoplasms after a longer period of follow-up.[77]
Sources: 77
A study from the CCSS reported on the risk of subsequent CNS neoplasms after a longer period of follow-up.[77]
The adjusted rate ratio of meningioma and gliomas in growth hormone–treated survivors of CNS tumors was 1.0 (95% CI, 0.6–1.8; P = .94), when compared with CNS tumor survivors who were not treated with growth hormone. This finding indicates negligible differences between the two groups for this particular risk.
A review of existing data suggests that treatment with growth hormone is not associated with an increased risk of CNS tumor progression or recurrence, or new or recurrent leukemia.[78]
Sources: 78
In general, the data addressing subsequent malignancies among childhood cancer survivors treated with growth hormone therapy should be interpreted with caution given the small number of events.[43,56,73-75,79,80]
As outlined in a consensus statement by the Growth Hormone Research Society, areas of uncertainty include the safety of growth hormone in children with cancer-predisposing conditions, its use in growth hormone–deficient children who are receiving maintenance therapy, and the overall benefit-risk ratio in adult survivors.[81]
Sources: 81
Treatment and outcomes associated with central precocious puberty
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Aside from the adjustment and psychosocial challenges associated with early pubertal development, precocious puberty can lead to the rapid closure of the skeletal growth plates and short stature. This deleterious effect can be further potentiated by growth hormone deficiency.[82,87]
The increased growth velocity induced by pubertal development can mask concurrent growth hormone deficiency with seemingly normal growth velocity; this occurrence may mislead care providers.[87]
Sources: 87
The impact of central precocious puberty on linear growth can be ascertained by assessing the degree of skeletal maturation (or bone age) using an x-ray of the left hand.[88]
Sources: 88
Delaying the progression of puberty relies on the use of various gonadotropin-releasing hormone agonist preparations. This approach has been shown to improve growth prospects, especially when other pituitary abnormalities, including growth hormone deficiency, are concurrently treated.[43,89]
Management of TSH deficiency
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Thyroid hormone replacement therapy using levothyroxine represents the mainstay of treatment of TSH deficiency.
The dose of levothyroxine needs to be adjusted solely using plasma free T4 levels. The levels of TSH are expected to remain low during therapy, given the central nature of this deficiency.
Central hypothyroidism should not be treated before assessment of the functioning of other hypothalamic-pituitary deficiencies, because it could precipitate an adrenal crisis in patients with ACTH deficiency.
Diagnosis and management
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
The diagnosis of ACTH deficiency should be suspected when low plasma levels of morning cortisol are measured (a screening cortisol level collected at 8 AM that is 10 µg/dL or more is reassuring for ACTH sufficiency, whereas a value of 5 µg/dL or lower is suspicious for insufficiency).
Confirmation is necessary using dynamic testing such as the low-dose ACTH stimulation test.[93]
Sources: 93
Because of the substantial risk of central adrenal insufficiency among survivors treated with cranial radiation doses exceeding 30 Gy to the hypothalamic-pituitary axis, endocrine monitoring with periodic dynamic testing as clinically indicated is recommended for this high-risk group.[43]
Sources: 43
Patients with partial ACTH deficiency may have only subtle symptoms unless they become ill.[43]
Sources: 43
Illness can disrupt these patients’ usual homeostasis and cause a more severe, prolonged, or complicated course than expected. As in complete ACTH deficiency, incomplete or unrecognized ACTH deficiency can be life-threatening during concurrent illness.
The treatment of ACTH deficiency relies on replacement with hydrocortisone, including stress dosing in situations of illness to adjust to the body’s physiologically increased need for glucocorticoids.[43]
Sources: 43
Body composition alterations after treatment for CNS tumors
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Among brain tumor survivors treated with higher doses of cranial radiation therapy, the highest risk of developing obesity has been observed in females treated at a younger age.[144]
Sources: 144
Survivors of craniopharyngioma have a substantially increased risk of developing extreme obesity because of the tumor location and the hypothalamic damage resulting from surgical resection.[145-148]
A cohort of 661 childhood survivors of brain tumors (mean follow-up time, 7.3 years) was evaluated for weight gain associated with hypothalamic-pituitary dysfunction. This cohort excluded survivors who had craniopharyngiomas or pituitary tumors.[149]
Sources: 149
Among survivors between the ages of 4 and 20 years at follow-up, 20.3% were classified as overweight and 8.5% had obesity, compared with 10.5% and 2.7%, respectively, in the general Dutch population of comparable age.
Hypothalamic-pituitary dysfunction was more prevalent in survivors who are overweight or have obesity than in survivors of normal weight.
BMI SDS at diagnosis, diagnosis of low-grade glioma, and history of diabetes insipidus and central precocious puberty were associated with weight gain, being overweight, or having obesity.
Posttherapy management
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
Clinicians should consider and encourage the administration of inactivated vaccines (e.g., influenza) and vaccines made of purified antigens (e.g., pneumococcus), bacterial components (e.g., diphtheria-tetanus-pertussis), or genetically engineered recombinant antigens (e.g., hepatitis B) in all cancer and transplant survivors according to recommended doses and schedules.[10-12]
Two primary doses of quadrivalent meningococcal conjugate vaccine should be administered 2 months apart to children with asplenia, from age 2 years through adolescence, and a booster dose should be administered every 5 years. For more information, see Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.[13]
Sources: Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 · 13
Two primary doses of quadrivalent meningococcal conjugate vaccine should be administered 2 months apart to children with asplenia, from age 2 years through adolescence, and a booster dose should be administered every 5 years. For more information, see Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.[13]
The efficacy of meningococcal vaccines in children with asplenia has not been established.
No known contraindication exists to giving these vaccines at the same time as other required vaccines, in separate syringes, and at different sites.
Pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV) are indicated at the recommended age for all children with asplenia.[14,15]
Pneumococcal conjugate vaccine (PCV) and pneumococcal polysaccharide vaccine (PPSV) are indicated at the recommended age for all children with asplenia.[14,15]
Following the administration of the appropriate number of doses of PCV13, PPSV23 should be administered starting at age 24 months.
A second dose should be administered 5 years later.
For children aged 2 to 5 years with a complete PCV7 series who have not received PCV13, a supplemental dose of PCV13 should be administered.
For asplenic individuals aged 6 to 18 years who have not received a dose of PCV13, a supplemental dose of PCV13 should be considered.
Hib immunization should be initiated at age 2 months, as recommended for otherwise healthy young children and for previously unimmunized children with asplenia.[15] For more information, see Immunization Schedules.[15]
Sources: 15 · Immunization Schedules · 15
Daily antimicrobial prophylaxis against pneumococcal infections is recommended for young children with asplenia, regardless of their immunization status.
Although the efficacy of daily antimicrobial prophylaxis has been proven only in patients with sickle cell anemia, this experience has been extended to other high-risk children, including asplenic children with a history of malignant neoplasms or thalassemia.
In general, antimicrobial prophylaxis (in addition to immunization) should be considered for all children with asplenia younger than 5 years and for at least 1 year after splenectomy.
The age at which antimicrobial prophylaxis is discontinued is an empiric decision.
The age at which antimicrobial prophylaxis is discontinued is an empiric decision.
On the basis of a multicenter study in sickle cell disease, prophylactic penicillin can be discontinued at age 5 years among those who are receiving regular medical attention and who have not had a severe pneumococcal infection or surgical splenectomy.
The appropriate duration of prophylaxis is unknown for children with asplenia attributable to other causes.
Some experts continue prophylaxis throughout childhood and into adulthood for particularly high-risk patients with asplenia.
Table 14 summarizes spleen late effects and the related health screenings.
Sources: Table 14
| Predisposing Therapy | Immunologic Effects | Health Screening/Interventions |
|---|---|---|
| GVHD = graft-versus-host disease; HSCT = hematopoietic stem cell transplant; IgA = immunoglobulin A; T = temperature. | ||
| aAdapted from the Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. | ||
| Radiation exposing spleen; splenectomy; HSCT with currently active GVHD | Asplenia/hyposplenia; overwhelming post-splenectomy sepsis | Blood cultures during febrile episodes (T >38.5°C); empiric antibiotics |
| Immunization for encapsulated organisms (pneumococcal, Haemophilus influenzae type b, and meningococcal vaccines) | ||
| HSCT with any history of chronic GVHD | Immunologic complications (secretory IgA deficiency, hypogammaglobulinemia, decreased B cells, T cell dysfunction, chronic infections [e.g., conjunctivitis, sinusitis, and bronchitis associated with chronic GVHD]) | History: chronic conjunctivitis, chronic sinusitis, chronic bronchitis, recurrent or unusual infections, sepsis |
| Examination: attention to eyes, nose/sinuses, and lungs | ||
For more information about posttransplant immunization, see the Centers for Disease Control and Prevention (CDC) Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients.
Development of thromboembolism during antileukemic therapy
Source: Late Effects of Treatment for Childhood Cancer (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 14, 2025. Captured 2026-09-09.
In a retrospective review of 208 children treated for ALL, investigators at McMaster University reported a 5.21-fold (95% CI, 1.82–14.91) increased odds of osteonecrosis among children who experienced thromboembolism during antileukemic therapy than among those who did not have a thromboembolism, even after accounting for age and asparaginase exposure.[59]
Sources: 59
Triangle